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ABSTRACT OF DISSERTATION

TELOMERASE REVERSE TRANSCRIPTASE IN ATHEROSCLEROSIS
Telomerase reverse transcriptase (TERT) is the catalytic subunit of
telomerase and the limiting factor for the enzyme activity. The expression of TERT
and telomerase activity is increased in atherosclerotic plaques. However, the role
of TERT dysregulation during atherosclerosis formation remains unknown.
The work herein first identified a multi-tiered regulation of TERT expression
in smooth muscle cells (SMC) through histone deacetylase (HDAC) inhibition.
HDAC inhibition induces TERT transcription and promoter activation. At the protein
level in contrast, HDAC inhibition decreases TERT protein abundance through
enhanced degradation, which decreases telomerase activity and induces
senescence. Furthermore, during vascular remodeling in vivo, TERT protein
expression in the neointima is prevented by HDAC inhibition. These data illustrate
a differential regulation of TERT transcription and protein stability by HDAC
inhibition. TERT is highly expressed in replicating SMC of atherosclerotic and
neointimal lesions. Using a model of guidewire-induced arterial injury, neointima
formation was reduced in TERT-deficient mice. Studies in SMC isolated from
TERT-deficient and TERT overexpressing mice with normal telomere length
established that TERT is necessary and sufficient for cell proliferation. TERT
deficiency did not induce a senescent phenotype but resulted in G1 arrest albeit
hyperphosphorylation of the retinoblastoma protein. This proliferative arrest was
associated with stable silencing of the E2F1-dependent S-phase gene expression
program which could not be reversed by ectopic overexpression of E2F1.
Chromatin immunoprecipitation and accessibility assays revealed that TERT was
recruited to E2F1 target sites to increase chromatin accessibility for E2F1 by
facilitating the acquisition of permissive histone modifications. These data indicate

a mitogenic effect of TERT on SMC growth and neointima formation through
epigenetic regulation of proliferative gene expression. Furthermore, TERT
expression is induced in activated macrophages during experimental and human
atherosclerosis formation. To investigate the role for TERT in lesional
macrophages and the subsequent effect on atherosclerosis formation, TERTdeficient mice were crossbred with LDL-receptor-deficient (LDLr-/-) mice to
generate first generation G1TERT-/-LDLr-/- offsprings, which were then further
intercrossed to obtain third generation G3TERT-/-LDLr-/- mice. G1TERT-/-LDLr-/mice revealed no telomere shortening while severe telomere attrition was evident
in G3TERT-/-LDLr-/- mice. When fed an atherogenic diet, G1TERT-/-LDLr-/- and
G3TERT-/-LDLr-/- mice were both protected from atherosclerosis formation
compared to their wild-type controls, indicating that genetic TERT-deletion
prevents atherosclerosis, and formation of the disease is not affected by telomere
attrition. Similarly, atherosclerosis development was decreased in chimeric LDLr/- mice with TERT deletion in hematopoietic stem cells after bone marrow
transplantation. TERT deficiency reduced macrophage accumulation in
atherosclerotic lesions and altered chemokine expression, including CXC1/2/3,
CCL3, CCL5, CCL21, CCR7, IL-6, and IL-1α. In isolated macrophages, gene
ontology (GO) enrichment analysis of silenced inflammatory genes indicated that
TERT positively regulates signal transducer and activator of transcription (STAT)
cascade, which was confirmed by the decreased tyrosine phosphorylation of
STAT3 protein resulting from TERT deletion. These findings indicate genetic TERT
deficiency decreases atherosclerosis formation by silencing inflammatory
chemokine transcription through inactivation of the STAT3 signaling pathway in
activated macrophages.
In conclusion, the dysregulation of TERT expression within atherosclerotic
plaques plays a causative role for vascular remodeling, including injury-induced
neointima formation and hypercholesterolemia-induced atherosclerosis, through
inducing SMC proliferation and a pro-inflammatory phenotype in infiltrating
macrophages. These findings unveil a mechanism of TERT exacerbating the
pathological vascular remodeling, which may provide a novel therapeutic target to
combating vascular diseases.
KEYWORDS: Telomerase, Vascular remodeling, Cell proliferation, Smooth
muscle, Macrophage, Inflammation
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CHAPTER ONE
Introduction

1.1

Atherosclerosis

1.1.1 Introduction
Atherosclerosis is the most common pathological process leading to
cardiovascular diseases. Fatty streaks, which can start in childhood, are the initial
atherosclerotic lesions as a result of macrophage infiltration and foam cell
accumulation. Fatty streaks seldom cause clinical events but gradually evolve into
complicated atheromatous plaques with a collection of immune cells, vascular
smooth muscle cells (VSMC), necrotic cores, calcified regions, modified lipids, and
foam cells. The chronic expansion of plaques narrows the lumen of the blood
vessel and eventually causes obstruction, resulting in ischemia of downstream
tissues. The clinical manifestations as a consequence of insufficient blood supply
include myocardial infarction, stroke, abdominal aortic aneurysms or lower limb
ischemia depending on the location of blocked vessel, which determines for a large
part the extent of morbidity and mortality1.
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1.1.2 Smooth Muscle Cell Proliferation in Atherosclerosis
VSMC are primarily distributed in the medial layer of the artery. Disturbed
laminar flow activates endothelium resulting in increased permeability of
lipoproteins and inflammatory dysfunction. Under inflammatory stimulation, medial
VSMC migrate into the intima and undergo dedifferentiation from a quiescent,
contractile phenotype towards a synthetic, proliferative state that contributes to
“intimal thickenings”. Therefore, abundant VSMC are found in the intima of specific
sites with low shear stress that are more susceptible to atherosclerosis formation.
Compared to the medial VSMC, the intimal VSMC are more mobile and proliferate,
and they produce pro-inflammatory mediators that attract other immune cells to
the site, thus creating the initial nidus for the development of atherosclerotic
lesions2.
Following activation and the subsequent inflammatory response of the
endothelial cell (EC), VSMC can proliferate under the stimulation of multiple growth
factors, including platelet-derived growth factor, transforming growth factor-β,
angiotensin II, epidermal growth factor and insulin-like growth factor 13. These
various growth factors initiate signals converging to a cascade of biochemical
events in the G1 phase of the cell cycle that permit cells to cross the G1/S
checkpoint into the S (synthesis) phase. For example, the transition of cells from
G1 to S phase in the cell cycle requires increased phosphorylation of
retinoblastoma tumor suppressor protein (Rb). In a hypophosphorylated state, Rb
sequesters the E2 factor (E2F) family of transcription factors, which are critical
regulators of G1/S transition, thus activates the transcription of genes encoding
2

the enzymatic and structural machinery for DNA synthesis and chromosomal
replication. Rb phosphorylation and subsequent E2F release are tightly controlled
by multiple positive regulators, such as cyclin and cyclin-dependent kinase (CDK)
complexes, and many negative effectors4. There are two families that prevent the
progression of the cell cycle, the CIP/KIP (CDK-interacting protein/Kinase
inhibitory protein) family and the INK4 (Inhibitor of Kinase 4) family. Members of
both families prevent progression of the cell cycle by inactivating cyclin-CDK
complexes. However, CIP/KIP inhibitors suppress the entire spectrum of CDKs,
while INK4 family mainly inhibits CDK4/6 and arrests the cell cycle in the G1 phase.
The CIP/KIP family includes p21, p27, and p57. p21 is activated by p53, which is
triggered by DNA damage. The INK4 family includes p15, p16, p18, and p195.
These positive and negative regulators of cell cycle, as well as their targets, are
outlined in Figure 1.1. The balance between the positive and negative branches of
cell cycle regulators is of paramount importance to VSMC proliferation in the
injured arterial wall and the initiation of atherosclerosis formation.Macrophages in
Atherosclerosis
Atherosclerosis is a nonresolving inflammatory condition with continual
recruitment of circulating monocytes into the intimal atherosclerotic lesions, where
they differentiate into macrophages and scavenge cholesterol to become foam
cells. During this process, both the lineage commitment and the functions of
macrophages in atherosclerotic lesions are also altered. These phenotypic
alterations of macrophages play important roles at all stages of lesion
progression6.
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It has been recognized that macrophages in atherosclerotic plaques
originate primarily from circulating monocytes instead of local proliferation of
tissue-resident macrophages7. Monocytes are derived from hematopoietic stem
cells (HSC), self-renewing stem cells in bone marrow that continuously replenish
all blood cell lineages.

Differentiation of HSC produces common myeloid

progenitor cells (CMP) and common lymphocyte progenitor cells (CLP), which
undergo further differentiations while gradually losing their self-renewing potential
and give rise to all types of blood cells along multiple lineages. CMP are the
precursor of granulocytes, macrophage progenitors (GMP), megakaryocyte and
erythroid progenitors (MEP), and macrophage and dendritic cell progenitors
(MDP). MDP are the immediate precursor of monocytes, macrophages and
dendritic cells but not granulocytes. Granulocytes, composed of basophils,
eosinophils and neutrophils, are derived from GMP8. The entire blood cell
collection with various flavors all as descendants of HSC (the process is known as
Hematopoiesis) is illustrated in Figure 1.2. Monocytosis as a result of a series of
successive proliferation/differentiation events from HSC, and MDP and an
increase in the number of circulating monocytes, could thus heighten the chance
of monocytes entering the arterial intima and expedite the development of
atherosclerosis. There are two subtypes of monocytes, Ly6C+ and Ly6C-9. During
inflammation, Ly6C+ monocytes infiltrate into the tissue and differentiate into M1
macrophages, which contribute to tissue degradation and T cell activation and are
distinguishable from other groups of macrophages by the secretion of proinflammatory cytokines such as TNFa and IL-610. In a steady state, Ly6C+
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monocytes differentiate into Ly6C- monocytes, which patrol the lumen through
crawling on the resting endothelium of blood vessels in healthy tissues. Ly6Cmonocytes are more likely to mature to M2 macrophages, which secrete antiinflammatory cytokines and contribute to tissue repair11.
Macrophages are the dominant immune cells in atherosclerotic lesions at
all stages of the disease. The inflammatory macrophage phenotype induced by
interferon-γ (IFN-γ) and the toll-like receptor 4 (TLR4) ligand lipopolysaccharide
(LPS) has been classically termed the M1 type. These stimuli initiate a strong
inflammatory program in the macrophage, which includes production of
proinflammatory cytokines and chemokines, inducible nitric oxide synthase (NOS)
producing large quantities of nitric oxide (NO), and production of reactive oxygen
species to aid in pathogen destruction. An alternative form of macrophages named
M2 subtype are induced by interleukin-4 (IL-4) and IL-13 and produce proresolving
molecules, such as IL-10 and transforming growth factor-β. The M2 macrophages
are involved in tissue remodeling and repair12. However, since the distinctive
characteristics for classifying the M1 and M2 subtypes are derived from
experiments in vitro, it is still an open question whether this classification bears
any significance when applied to in vivo conditions. The phenotype of the lesional
macrophages, which are exposed to a plethora of stimuli, is more complex as it
constantly responds to dynamic cues from the microenvironment by intracellular
signal-relaying cascades and therefore could change with the progression of the
disease. Nevertheless, the pro-inflammatory macrophages have been shown to
be the dominant phenotype advanced human endarterectomy lesions, where IFN-
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γ is more abundant than IL-413. The inflammatory responses of macrophages are
the result of an intricate network of signal transductions and gene expressions. For
example, activation of the TLR pathway triggers nuclear factor kappa-light-chainenhancer of activated B cells (NF-κB) and Mitogen-activated protein kinases
(MAPK) to initiate their respective signaling network, which amplify the original
signal into the expression of thousands of inflammation-related genes14.
Therefore, the net proatherogenic effect of lesional macrophages is likely due to
the highly complex crosstalk between various cytokines and their signaling
effectors, which can be differentially triggered by a broad spectrum of stimuli. The
process accompanying proinflammatory macrophage activation mainly includes
three inflammatory pathways: signal transducer and activator of transcription
(STAT) molecules activated by IFNγ binding to its receptor, NFκB and MAPK
triggered by the activation of TLR or tumor necrosis factor (TNF) receptor)15, 16.
Activation of STAT protein is an essential corresponding downstream effect of
TLR4 and IFNɣ signaling pathways17. Therefore, the STAT proteins are described
as central signaling molecules that control cellular adaption and functional
reprogramming in response to environmental stimuli or stress18. A large number of
cytokines, growth factors, and hormones function as the ligand to activate STAT
pathways by binding to their membrane receptors, which subsequently triggers the
phosphorylation of Janus kinase (JAK). JAK proteins are receptor-associated
protein tyrosine kinases that activate STAT proteins by tyrosine phosphorylation.
The STAT proteins are latent transcription factors residing in the cytoplasm which
translocate to the nucleus when phosphorylated and activate transcription of target
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genes19. The JAK/STAT signaling pathway is actively involved in regulating
atherosclerosis formation. Secretion of pro-atherosclerotic cytokines and
chemokines by macrophages in atherosclerotic lesions, which is a critical
pathogenic step has been specifically attributed to activation of the IL-6/STAT3
signaling pathway20-24.

1.2

Telomerase Reverse Transcriptase

1.2.1 Regulation of Telomerase Reverse Transcriptase
1.2.1.1 Introduction
Telomerase reverse transcriptase (TERT) is the catalytic subunit of
telomerase, which is a ribonucleoprotein that synthesizes telomere repeat
sequences to protect telomeres from replicative erosion25. TERT is the limiting
factor for telomerase activity in both cancer and normal somatic cells. It is critical
for the maintenance and stabilization of linear chromosomes and the regulation of
cellular senescence and immortalization26. In the biological system, TERT
expression is closely regulated in a context-dependent manner via a multi-tiered
regulatory network involving genetic and epigenetic controls, post-transcriptional
regulation and post-translational modification27. The transcriptional control is the
primary and rate-limiting regulation of TERT expression in many cells, for example,
TERT is transcriptionally repressed in most human somatic cells and is
upregulated through TERT promoter activation in most cancer cells28. The TERT
promoter contains binding sites for a number of transcription factors involved in
cellular

proliferation,

apoptosis,

differentiation,
7

inflammation,

and

tumorigenesis27, 29. For example, our previous studies have uncovered diseaserelevant/pathogenic VSMC proliferation as a result of TERT up-regulation by
binding of Ets-1 or E2F1 to the TERT promoter 30,

31 .

Alternative transcript

splicing of TERT as a result of the post-transcriptional regulation has been
documented in many human tissues and cell lines, and likely plays a role in the
regulation of telomerase activity and other cellular functions by TERT. The human
TERT gene contains 16 exons and can be spliced into multiple isoforms. None of
the identified alternatively spliced forms of TERT gene has reverse transcriptase
activity, thus they cannot reactivate telomerase and elongate telomeres. Although
it is assumed that most variants are degraded and unlikely translated into proteins,
some TERT isoforms have been shown to be potentially oncogenic32. The
observation that the abundance of TERT protein does not translate into telomerase
activity leads to the discovery of post-translational modifications, e.g., the
phosphorylation of specific serine, threonine, or tyrosine residues, as an important
regulatory mechanism for TERT activity. These phosphorylation events facilitate
TERT nuclear translocation thereby allowing for assembly of active telomerase to
elongate telomeres33.

1.2.1.2. Epigenetic Regulation of TERT Expression
Among the multilayered control of TERT expression and function described
above, the chromatin environment and epigenetic status of the endogenous TERT
locus are also pivotal for the regulation of TERT mRNA level. Epigenetic regulation
of TERT expression is mainly achieved through tagging of the histone core
8

complexes and methylation of the CpG loci near the promoter region34. In
eukaryotes, genomic DNA is wrapped around histone octamers each composed
of two tetramers of H2A, H2B, H3 and H4 subunits to form structural units known
as nucleosomes, which can be further condensed into higher-order chromosomal
architectures. Such tightly bundled configuration blocks the access of promoters
and regulatory elements on the DNA by transcription-associated factors and the
transcriptional machinery. To allow dynamic access to condensed DNA, chromatin
and nucleosomes can be dynamically restructured in a process called chromatin
remodeling, in which various covalent labels are added to or removed from the
histone proteins that signal to the ATP-powered remodeling complexes which
actually perform the restructuring35. The N-terminal tails of the histones are subject
to a variety of covalent modifications including acetylation, methylation,
phosphorylation, and ubiquitination36. Histone hyperacetylation, which can be
enhanced by unchecked activity of histone acetyltransferase (HAT), marks active
transcription due to the uncoiling of DNA and histones. On the other hand, removal
of these acetyl groups by histone deacetylases (HDAC) reduces accessibility of
the modified regions by allowing the chromatin to acquire a more compact
conformation36. HDAC can be inhibited by a class of competitive inhibitors, which
facilitates stable histone acetylation resulting in enhanced nucleosomal
unwrapping and activates gene transcription within chromatin regions that are
otherwise heavily condensed37. In human somatic cells that are terminally
differentiated, the TERT gene locus lies within a compact, nuclease-resistant
chromatin domain and remains inactive.
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The fact that HDAC inhibitors can

increase TERT transcription, as shown in multiple studies, suggests that native
chromatin environment, i.e., formation of heterochromatins, is critical for the tight
regulation of TERT during cell proliferation and differentiation38-41.

1.2.2 Function of TERT
1.2.2.1 Telomeric Functions of TERT
Because of the “end replication problem”, the failure of the DNA replication
machinery to replicate the end of linear chromosomes, chromatin erosion at the
termini occurs in each round of DNA replication cycles in eukaryotic organisms.
Telomeres, the repetitive DNA-protein complexes at the end of chromosomes, not
only act as a buffer to counteract replication-associated shortening, but also
conceal linear chromosome ends from being falsely identified as strand breaks and
subject to inappropriate repair which usually results in detrimental chromosomal
fusions42. Over time telomeres become critically shortened with successive cell
divisions, which triggers replicative senescence, a status in which cells
permanently exit cell cycle. As a result, normal somatic cells can only proliferate
for a limited number of times/generations predetermined by their telomere length,
the molecular basis for cellular senescence and normal human aging43.
Telomerase is an enzyme that maintains the integrity of telomeres by adding
telomeric repeats to chromosome ends. Telomerase is composed of a catalytic
subunit TERT, an RNA-containing subunit and associated proteins. The
telomerase RNA serves as the template for reverse transcription by TERT 25. In
humans, telomerase is ubiquitously expressed during the first weeks of
10

embryogenesis, after which it is generally repressed throughout embryonic
development and remains inactive in normal somatic human cells, while in
activated lymphocytes, germ line cells, stem cells, and cancer cells, the enzyme
activity is maintained44. Although TERT transcription is undetectable in matured
somatic cells, its level is elevated during telomerase reactivation. Furthermore,
telomerase activity can be fully restored by ectopic expression of TERT. Therefore,
TERT is recognized as the most important limiting subunit for telomerase activity26.
Transcriptional regulation of TERT expression is suggested to be the dominant
regulatory mechanism for the silencing of telomerase during cellular differentiation
as well as its reactivation during carcinogenesis27. Moreover, TERT-deficient mice
exhibit significantly telomere erosion and phenotypes associated with telomere
shortening, such as the loss of tissue renewal, in late generations of the TERTdeficient lineage obtained by successive cross-breeding of heterozygous TERTdeficient mice45. Thus, TERT is necessary and crucial for telomerase activity and
the maintenance of telomere integrity.

1.2.2.2 Non-Telomeric Functions of TERT
In addition to telomere elongation, accumulating evidence indicates that
TERT also has fundamental functions that are independent of its enzymatic
activity. These non-telomeric functions of TERT are broadly associated with the
regulation of gene expression, modulation of cellular signaling, cell cycle
regulation, reducing reactive oxygen species release, protection of mitochondria,
inhibition of apoptosis, promotion of cellular and organismal survival, and
11

modulation of DNA damage response46-48. In addition, TERT was found to shuttle
between different cellular compartments where specific localization can change
under a variety of conditions, such as during the progression through different cellcycle stages, cellular transformation and when the cells suffer from extensive DNA
damage49. This observation further reinforces the notion of telomere-independent
functions of TERT involved in different cell signaling pathways when targeted to
different locations or responding to different stimulations.
Among these telomere-independent activities of TERT, the role of TERT in
gene transcription has been investigated in detail. Experiments of global
expression profiling or single specific gene analysis have shown that TERT affects
the expression of hundreds of genes, which involve in diverse cellular processes
including growth control, energy metabolism, apoptosis, DNA damage response,
wound healing, tumor metastasis and angiogenesis50-56. Similarly, our previous
study also identified an extra-telomeric role of TERT in macrophage expression of
matrix

metalloproteinase-2

(MMP-2)

during

abdominal

aortic

aneurysm

formation57. To date, how TERT is involved in gene transcription is largely
unknown. It has been suggested that TERT may function as transcription effector
to recruit other transcription factors. For example, TERT interacts directly with the
nuclear factor NF-kB p65 subunit to stimulate inflammatory gene expressions58.
More emerging evidence indicates that TERT participates in the modulation of
chromatin architecture. For example, TERT alters histone tail modification and
chromatin in cells lacking TERT is more susceptible to micrococcal nuclease
digestion59. TERT also interacts with transcription activator BRG1, which is a
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component of ATP-dependent chromatin remodeling complexes and has helicase
and ATPase activities. The interaction between TERT and BRG1 regulates the
expression of genes involved in the Wnt signaling pathway and contributes to
heterochromatin assembly at locations distinct from telomeres60. These findings
imply novel molecular mechanisms of TERT in many essential cellular processes
by targeting genes and pathways beyond its well defined function in telomere
biology.
In summary, the canonical function of TERT is telomere elongation as a
component of telomerase. However, accumulating evidence indicates various nontelomeric functions of TERT, including regulating the expression of a broad
spectrum of genes. As a transcription regulator, TERT may be present in different
protein complexes and play essential parts in modulating chromatin structures
(Figure 1.3). However, the mechanisms by which TERT controls gene transcription
remain controversial and require further investigation.

1.2.3 Telomere and Telomerase Homeostasis in Atherosclerosis
1.2.3.1 Introduction
Telomere attrition serves as a key checkpoint in the control of cell
proliferation by triggering replicative senescence. Therefore, telomere-based
senescence has been closely implicated in cancer development and aging44.
Telomerase activity and TERT expression are upregulated in most cancer cells in
support of unrestrained cellular proliferation. On the other hand, lack
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of telomerase activity in human somatic tissues and concomitant telomere erosion
correlates with age-related pathologies61, 62. Telomere-associated gene mutations,
e.g. TERT or TERC, result in accelerated telomere shortening, which is the cause
of three human disorders, dyskeratosis congenita63, multiple different diseases
collectively characterized by bone marrow failure64, and idiopathic pulmonary
fibrosis65. Their clinical presentation is associated with an impaired proliferative
capacity of cells in tissues requiring constant renewal, i.e. skin, oral mucosa and
bone marrow, indicating the capacity to maintain adequate telomere length is vital
for tissues with high proliferative potential. Telomerase reactivation by
overexpressing TERT in cancer-resistant mice extends lifespan, supporting the
hypothesis that repressed telomerase supports cancer resistance at the cost of
longevity66. Conversely, this trade-off for cancer resistance increases the risk for
age-related degenerative diseases67. Generally, telomeres erode with age, and
reflect a cell’s past proliferative history and future propensity for apoptosis,
senescence, and transformation. However, it remains controversial whether
telomere shortening contributes to the aging process and aging-related diseases,
including atherosclerosis68. Moreover, contrary to the general concept of the agingassociated

telomere attrition, telomeres

are

actually elongated

in the

atherosclerotic plaques, a result of increased TERT expression and activated
telomerase, the extent of which correlates with the severity grade of
atherosclerosis69-71.

Therefore,

during

the

pathogenesis

of

specifically

atherosclerosis formation, telomeres may change differently in peripheral blood
leukocytes and cells within local tissues. Also, together with elongated telomeres,
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the upregulated TERT expression and reactivated telomerase within the arterial
intima suggest a functional involvement of the telomeric system in vascular
remodeling.

1.2.3.2 Telomere and Telomerase Homeostasis in Endothelial Cells
Aging is a major risk factor for the initiation and the development of
atherosclerosis. There is growing evidence about telomere biology and cell
senescence involved in the pathogenesis of cardiovascular diseases. Telomere
shortening in EC was observed during atherosclerosis formation, which is
considered to be caused by oxidative stress as a consequence of the disturbed
blood flow72. Meanwhile, EC in human atherosclerotic lesions present a
senescence-associated phenotype which can be rescued by ectopic expression of
TERT using viral transduction73. Chronic oxidative stress and diminished activation
of PI3K/AKT pathway may be the underlying mechanism bridging telomeric
aberrations and loss of EC viability74. However, until now there is little proof to
show a direct effect of TERT on stress-induced premature senescence of EC
during atherosclerosis formation.

1.2.3.3 Telomere and Telomerase Homeostasis in Smooth Muscle Cells
The differentiation and maturation of human somatic cells occur with the
suppression of TERT expression and telomerase activity. As telomeres shortens
with each replication cycle, these cells gradually lose replicative competency and
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permanently exit cell cycle43. However, accumulating evidence suggests that
during tissue renewal and healing processes, expression of TERT can be induced
in response to various environmental cues, which enhances cell multiplication in
the time of need27. Similarly, inducible expression of TERT has been shown in
proliferating SMC during neointima and atherosclerosis formation30,

31.

Multiple

mechanistic models that link the activation of telomerase and proliferation of VSMC
have been proposed. Minamino et al. demonstrated that TERT activation through
phosphorylation and the subsequent nuclear translocation accounts for
telomerase-driven cell life span75. In addition, our previous study has identified that
TERT is the key factor that mediates the restenosis-preventing effect of
everolimus, which coats the stent and limits tissue overgrowth. SMC proliferation
is dependent on the expression of TERT which facilitates E2F1 binding to S-phase
gene promoters76.
VSMC within human atherosclerotic plaques displays a senescence
phenotype with a limited proliferative capacity77. These cells present low level of
TERT expression and short telomeres78, indicating that a TERT-associated
premature cellular senescence phenotype may participate in the pathogenesis of
human atherosclerosis.

1.2.3.4 Telomere and Telomerase Homeostasis in Inflammation
Age-associated immune deficiency is considered a major contributory factor
to the increased frequency of morbidity and mortality among the elderly. Adaptive
immunity of ageing individuals deteriorates because of a progressive decline of
16

global T cell and B cell populations, possibly as a consequence of the exhaustion
of the available pools of naïve lymphocytes and along with their predecessors. The
innate immunity of aging individuals, however, is relatively well preserved although
age-dependent alterations are frequently observed79. Inflammation plays a crucial
role for the development of atherosclerosis. The presence of short LTL in human
atherosclerosis can be mainly attributed to increased leukocyte turnover during
inflammation and the following accelerated telomere loss per replication80.
Similarly, telomere shortening in T lymphocytes and accelerated leukocyte
turnover are evident in patients with chronic infection and inflammatory disease81,
82.

Therefore, telomere shortening is considered to be a feature of

immunosenescence characterized by a decreased ability to produce antibodies,
the decline in phagocytosis and cellular migration, as well as a reduction of cell
numbers83. Although atherosclerosis is an age-related disease, telomere erosion
in mice shows an atheroprotective effect. The late generation TERC-knockout
mice

on

an

apolipoprotein

E-deficient

background

developed

fewer

atherosclerotic lesions, which has been associated with an impaired proliferative
capacity of macrophages and lymphocytes84. Therefore, telomere attrition might
cause cellular senescence, and apoptosis in difference cell types, but have
variable effects on complex disease processes in a tissue-specific pattern.
Immune cells are unique among normal somatic cells as the activated
phenotype can up-regulate telomerase and limit telomere attrition in the process
of continued cell proliferation. Telomerase activity and TERT expression in
immune cells have been demonstrated to be elevated during viral or bacterial
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infection, as well as in a variety of chronic diseases related with low-grade
inflammation, including atherosclerosis, idiopathic pulmonary fibrosis, rheumatoid
arthritis, and systemic lupus erythematosus85. Consistent with the dysregulation of
TERT and telomerase in both acute and chronic scenarios of inflammation,
telomerase activity and TERT expression have been shown to regulate the
secretion of inflammatory cytokines58, 86-89.
Considering these collectively findings described above, TERT protein
expression and telomerase activity are inducible in various cell types circulating
in the vessel and telomere shortening in genetic models may impact vascular
dysfunction. However, whether TERT deficiency and loss of telomerase activity
play a causal role in vascular remodeling and atherosclerosis formation is
incompletely understood.

1.3

Hypothesis and Specific Aims
The

cellular

mechanisms

underlying

vascular

remodeling

during

atherosclerosis formation include endothelial cell activation and subsequent
macrophage infiltration. Among the many proteins and enzymes implicated in
tissue repair, telomerase is recognized as one of the most important proteins
involved in remodeling processes. However, its role in inflammation and vascular
disease remains unknown. Our recent studies have confirmed an increased
expression of TERT in atherosclerosis and after vascular injury30, 31, 71, 32, 72. TERT
is highly induced by mitogenetic and atherogenic stimulation in SMC and
macrophages. However, the role of TERT dysregulation within the arterial intima
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and the consequence of inducible vascular TERT overexpression in the process
of vascular remodeling remains unknown.

Aim One: TERT transcription is dependent on chromatin remodeling, and HDAC
inhibition prevents atherosclerosis formation and neointima formation. Therefore,
the first aim is to define whether and how pharmacological HDAC inhibition targets
TERT expression during proliferative vascular remodeling.

Aim Two: Aberrant proliferation of VSMC in response to injury induces
pathological vascular remodeling during atherosclerosis and neointima formation.
Telomerase is the rate-limiting factor for cell replication and tissue renewal whose
physiological roles in vascular diseases remains to be determined. Therefore, the
second aim is to determine whether TERT affects proliferative vascular remodeling
and to identify the molecular mechanism of TERT-driven VSMC proliferation.

Aim Three: TERT is highly induced by atherogenic lipoproteins and inflammatory
cytokines in macrophages. Thus, we will continue to investigate the function of
TERT overexpression in macrophages during atherosclerosis formation. The third
aim is to define the role and mechanisms of TERT in macrophage activation and
the consequent development of atherosclerosis.
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Figure 1.1 The Regulation of Cell Cycle.
Cyclins and cyclin-dependent kinase (CDK) complexes are the positive
regulators to drive cell cycle forward. Conversely, the INK4 family (p15, p16,
p18, and p19) and CIP/KIP family (p21, p27, and p57) are the main inhibitors to
inactivate cyclin-CDK complexes and halt the progression of the cell cycle.
Besides, P53, triggered by DNA damage, is another negative master to stop the
cell cycle by promoting P21 production. p14 prevents the degradation of p53,
thus links to the p53/p21 pathway to inhibit cell-cycle progression.
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Figure 1.2 Development to Macrophages from Hematopoietic Stem Cells.
The figure illustrates the differentiation pathways of hematopoietic stem cells
(HSC) that give rise to the various hematopoietic cell lineages. CLP, common
lymphoid progenitors; CMP, common myeloid progenitors; GMP, granulocyte
and macrophage progenitors; MDP, macrophage and dendritic cell progenitors;
MEP, megakaryocyte and erythroid progenitors; DC, dendritic cell; NK, natural
killer.
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Figure 1.3 Functions of Telomerase Reverse Transcriptase
The canonical function of telomerase reverse transcriptase (TERT) is the
maintenance of telomere integrity. Alternatively, TERT may function as a
transcription cofactor or participate in chromatin remodeling, thus playing a role
in the regulation of gene expression. The genes that might be regulated by TERT
are involved in many essential cellular functions and biological processes, such
as cell growth, DNA damage response, apoptosis, inflammation, angiogenesis,
and metastasis. These extra-telomeric functions of TERT may play an important
part in tumorigenesis. In addition, under oxidative stress, TERT translocates
from nucleus to mitochondria, which could modify mitochondrial functions such
as its metabolic capacity, energy efficiency and reactive oxygen species (ROS)
production by the electron transferring complexes.
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CHAPTER TWO

Differential Regulation of Telomerase Reverse Transcriptase
Promoter Activation and Protein Degradation by Histone Deacetylase
Inhibition

2.1

Abstract
Telomerase reverse transcriptase (TERT) maintains telomeres and is rate

limiting for replicative life span. While most somatic tissues silence TERT
transcription resulting in telomere shortening, cells derived from cancer or
cardiovascular diseases express TERT and activate telomerase. In the present
study, we demonstrate that histone deacetylase (HDAC) inhibition induces TERT
transcription and promoter activation. At the protein level in contrast, HDAC
inhibition decreases TERT protein abundance through enhanced degradation,
which decreases telomerase activity and induces senescence. Finally, we
demonstrate that HDAC inhibition decreases TERT expression during vascular
remodeling in vivo. These data illustrate a differential regulation of TERT
transcription and protein stability by HDAC inhibition and suggest that TERT may
constitute an important target for the anti-proliferative efficacy of HDAC inhibitors.

2.2

Introduction
Telomeres are repetitive DNA sequences which protect the ends of

chromosomes and are maintained by the catalytic activity of telomerase reverse
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transcriptase (TERT)90. Since most adult somatic cells transcriptionally repress
TERT, telomeres shorten progressively during tissue renewal 91. This telomere
shortening has been suggested to limit the replicative potential and ultimately
induce cellular senescence92. Conversely, TERT expression is induced and
telomerase is activated during cancer and atherosclerosis development, both
being the most prevalent human diseases70,

71, 93.

The observation that TERT

overexpression induces cancer formation94, 95 and provides an unlimited mitotic
potential96 has suggested a permissive role for TERT to sustain cancer cell
proliferation. Consequently, there has been significant interest to develop targeted
TERT therapeutic approaches, which are currently being tested in clinical trials 97.
While a critical contribution of TERT to oncogenesis has been welldescribed, its role in atherosclerosis and neointima formation remains unknown.
TERT expression and telomerase activity are induced during atherosclerosis
formation and in response to vascular injury30, 70, 71. At the cellular level, mitogenic
stimulation induces TERT transcription and telomerase activity in vascular smooth
muscle cells (VSMC)

98.

In vitro, this transient expression of TERT is both

necessary and sufficient for the proliferation of VSMC30, 31, pointing to an important
function of TERT for the proliferative response underlying vascular disease.
Because TERT transcription is dependent on chromatin remodeling 99, we
investigated in the present study whether inhibition of histone deacetylation
induces TERT transcription. Furthermore, since histone deacetylase (HDAC)
inhibition prevents atherosclerosis formation and neointima formation 100, 101, we
evaluated whether pharmacological HDAC inhibition targets TERT expression
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during proliferative vascular remodeling. We provide direct evidence that inhibition
of histone deacetylation activates TERT transcription but decreases its protein
stability, ultimately resulting in repression of telomerase activity and senescence,
mechanisms that likely contribute to the inhibition of neointima formation by HDAC
inhibitors.

2.3

Materials and Methods

Cell Culture
Rat aortic vascular smooth muscle cells (VSMC) were purchased from
Lonza and maintained in DMEM supplemented with 10% FBS. Cells were starved
in serum-free DMEM for 24 hours, pretreated with Scriptaid (Enzo Life Sciences)
at the indicated doses for 30 min and stimulated with 10% FBS for the indicated
time points. For protein stability assays, 10 µg/ml cycloheximide (Sigma) was
added to cell cultures to inhibit protein synthesis, and cytosolic and nuclear
proteins were harvested subsequently at the indicated time points.

Quantitative Real-time RT-PCR
Total RNA was isolated with TRIzol® (Invitrogen) and reverse transcribed
into cDNA using SuperScript II (Invitrogen). RNA expression of target genes was
quantified using an iQTM SYBR Green Supermix (BioRad). Primers used in this
study are as follows: TERT, forward: 5’-GTACAGCTGCTGAGGTCATTCTT-3’;
reverse: 5’-AAACACTGGGTCTGCTTCTTTTT-3’; P16, forward: 5’25

GGTCACCGACAGGCATAACTTC-3’; reverse: 5’AAAGGAGGGCTGAGGCCTAA-3’; P21, forward: 5’CCGGGAGAACATGTATTTTGGT-3’; reverse: 5’GGGTGTAAAGATTCGGGACAGT-3’; GADD45, forward: 5’TGGTGACGAACCCACATTCA-3’; reverse: 5’-ACTGGCACCCACTGATCCAT-3’;
RPL3A, forward: 5’-GTACGCTGTGAGGGCATCAA-3’; reverse: 5’CTCGAGACGGGTTGGTGTTC-3’. Samples were analyzed in triplicate and
normalized to expression values of the housekeeping gene RPL3A. Data were
calculated using the 2-CT method102.

HDAC siRNA Transfection
siRNA experiments were performed using the SMARTpool technology
(Dharmacon RNA Technologies), which provides a mix of four different proprietary
siRNAs specific for the target gene. VSMC were transfected with HDAC1, HDAC2,
HDAC3 or scrambled siRNA (50 nM) using LipofectamineTM RNAiMAX (Invitrogen)
for 6 hours. Following transfection, cells were recovered in growth media overnight,
serum-deprived for 24 hours and stimulated with growth media for 24 hours before
collecting RNA.

Plasmids, Transient Transfections and Luciferase Assays
The TERT promoter constructs have been described previously31. VSMC
were transiently transfected with 1.0 µg TERT promoter construct using
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Lipofectamine 2000 (Invitrogen) in OPTI-MEM. Following transfection, cells were
serum deprived, treated with 6 µM Scriptaid and stimulated with complete growth
media for 24 hours. Luciferase activities were analyzed using a Dual Luciferase
Reporter Assay (Promega). Transfection efficiency was normalized to Renilla
luciferase activities generated by cotransfection of pRL-null-renilla.

Western Blotting
Cytosolic and nuclear fractions were isolated using a Nuclear and
Cytoplasmic Extraction Kit (Thermo Scientific) and protein was subjected to routine
immunoblotting using the following antibodies: TERT (Rockland 600-401-252S),
TBP (Abcam ab818) and GAPDH (Sigma G9545). Expression of GAPDH and TBP
was used to assess for equal protein loading for cytosolic and nuclear
compartments, respectively.

Telomerase Activity Analysis
Telomerase activity was measured using a quantitative Telomerase
Detection Kit (Allied Biotech Inc.) per manufacturer’s instructions. Telomerase
activity was quantified by real-time PCR using whole-cell extract containing 0.5 µg
of protein.
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Senescence Analysis
VSMC were treated with Scriptaid at the indicated doses for 48 hours and stained
overnight for β-galactosidase activity using a Senescent Cell Histochemical
Staining Kit (Sigma CS0030) according to the manufacturer’s instructions.

Endovascular Femoral Artery Guide Wire Injury
Guide wire endothelial denudation injuries were performed in C57BL/6J
mice (The Jackson Laboratory) at 8 weeks of age as described 30. Twelve mice
were injected with Scriptaid or DMSO the day before injury, on the day of the injury,
and every other day thereafter for 28 days. The dose of Scriptaid (3.5 µg/g body
weight intraperitoneally) used in this study was based on the doses used in our
previous Scriptaid study101. All procedures on mice were approved by the
institutional animal care and use committee at the University of Kentucky.

2.4

Results

2.4.1 TERT Transcription Is Induced by HDAC Inhibition
To first evaluate whether histone acetylation affects TERT transcription, we
employed the HDAC inhibitor Scriptaid, which potently suppresses histone
deacetylation in vascular cells and inhibits VSMC proliferation 101, 104. As depicted
in Figure 2.1 A-B, pre-treatment of VSMC with previously published doses of the
HDAC inhibitor Scriptaid induced TERT mRNA expression in a time- and dosedependent manner105. At the employed doses and kinetics Scriptaid did not induce
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apoptosis, as assessed by Annexin V and propidium iodide staining (data not
shown). In order to establish specificity of this pharmacological approach and to
identify specific HDAC that regulate TERT mRNA expression, we next employed
siRNA-knockdown of HDAC1, 2 and 3 in VSMC. Depletion of HDAC1, but not
HDAC2 or HDAC3, significantly increased TERT transcript levels (Figure 2.1 C).
To further evaluate the mechanism by which HDAC inhibition regulates TERT
transcription, we next analyzed TERT promoter activity in Scriptaid-treated VSMC.
Transient transfection of a luciferase reporter driven by the full-length TERT
promoter revealed a solid induction of TERT promoter activity in response to
HDAC inhibition by Scriptaid (Figure 2.1 D). Collectively, these findings confirm
that pharmacological HDAC inhibition and HDAC1 depletion induce TERT
transcription in VSMC.

2.4.2 HDAC Inhibition Decreases TERT Protein Levels and Suppresses
Telomerase Activity
We next analyzed whether the induction of TERT transcription by HDAC
inhibition translated into increased TERT protein expression levels. However,
surprisingly Scriptaid treatment potently decreased both nuclear (Figure 2.2 A) and
cytoplasmic (Figure 2.2 B) TERT protein levels in a dose-dependent fashion. Since
TERT is the limiting factor for telomerase activity, we further analyzed whether
HDAC inhibition reduced the enzymatic activity of TERT. Consistent with the noted
decline in TERT protein mass, inhibition of HDAC activity by Scriptaid significantly
attenuated telomerase activity in VSMC (Figure 2.2 C). Albeit inducing TERT
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transcription, these observations indicate that HDAC inhibition ultimately
decreases TERT protein mass resulting in a decline of telomerase activity.

2.4.3 HDAC Inhibition Accelerates TERT Protein Degradation
Since Scriptaid decreased both nuclear and cytoplasmic TERT expression,
we reasoned that HDAC inhibition might decrease protein stability rather than
enhance nuclear export. Consistent with this notion, HDAC inhibitors have been
previously reported to trigger protein degradation106. To address this question, we
pretreated VSMC with vehicle or Scriptaid and performed a chase experiment after
inhibiting protein de novo synthesis with cycloheximide. As depicted in Figure 2.3,
Scriptaid treatment significantly decreased TERT protein stability compared to
vehicle treatment. Therefore, HDAC inhibition may destabilize TERT protein
through post-translational modifications, an effect that ultimately prevails over
increased transcription induced by histone acetylation.

2.4.4 HDAC Inhibition Induces VSMC Senescence
Depletion of telomerase activity induces telomere shortening and replicative
senescence92. Therefore, we next investigated whether the depletion of TERT
induced by HDAC inhibition resulted in cellular senescence. As expected and
depicted in Figure 2.4 A, Scriptaid treatment of VSMC induced β-galactosidase
expression, a well-established biomarker of senescence107. Furthermore, Scriptaid
treatment induced a gene expression program implicated in cellular senescence,
including transcript levels of p16, p21 and GADD45 (Figure 2.4 B). In concert,
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these experiments demonstrate that the decline in telomerase activity induced by
HDAC inhibition is associated with VSMC senescence.

2.4.5 HDAC Inhibition Reduces TERT Expression in Neointima Following
Vascular Injury
Pharmacological HDAC inhibitors suppress cell proliferation108, and in our
previous studies we demonstrated that HDAC inhibition by Scriptaid attenuates the
proliferative response underlying pathological neointima formation 101. Based on
our in vitro data, we hypothesized that HDAC inhibition might suppress TERT
expression in vivo during pathological neointima formation in response to vascular
injury. To address this question, we analyzed TERT expression in femoral arteries
of mice treated either with vehicle (DMSO) or Scriptaid and subjected to vascular
injury using a model of endothelial denudation injury101. As depicted in Figure 2.5
A, nuclear TERT expression was highly induced during neointima formation. In
contrast, the inhibition of neointima formation by the HDAC inhibitor was
associated with significantly decreased vascular TERT expression, even after
normalization for the reduced neointimal area (Figure 2.5 B). This finding
establishes that TERT expression in the neointima is suppressed by HDAC
inhibition, which may contribute to the prevention of neointimal VSMC proliferation
observed with HDAC inhibition.
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2.5

Discussion
Inhibition of histone deacetylation through pharmacological approaches is

currently being evaluated in clinical trials as a novel promising anti-proliferative
therapy109. During vascular remodeling, HDAC inhibitors potently prevent
neointima formation and inhibit aberrant VSMC proliferation 101. Although
telomerase activation constitutes a key mechanism implicated in the replicative
potential of a cell91-93, the regulation of TERT by HDAC inhibition and its
importance as pharmacological target for the anti-mitotic efficacy of HDAC
inhibitors in vascular cell types have previously not been evaluated. In the present
study, we demonstrate that both pharmacological inhibition and genetic depletion
of HDAC activate TERT transcription. However, TERT protein levels and
telomerase activity are potently inhibited by HDAC inhibition due to accelerated
protein degradation. This inhibition of TERT expression results in cellular
senescence, an effect that likely contributes to the anti-proliferative efficacy of
HDAC inhibitors during neointima formation in response to vascular injury.
TERT constitutes the limiting factor for the catalytic activity of telomerase110.
While TERT expression is inherently associated with aberrant cell proliferation 93,
most normal somatic cells epigenetically silence TERT promoter activity by DNA
methylation and histone deacetylation111,

112.

However, during the activation of

malignant cell proliferation, transcription factors sequester HDAC from the TERT
promoter allowing subsequent histone acetylation and transcription from the
promoter113. Similarly as during cancer formation, aberrant VSMC proliferation
constitutes a hallmark of atherosclerosis development and neointimal remodeling2.
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During this proliferative process, VSMC transcriptionally induce TERT expression
and telomerase activity, which are required for their mitotic response 30, 31. To our
knowledge, data presented here are the first to establish that inhibition of HDAC
activity or HDAC1 depletion activates TERT transcription in VSMC. Our
observation that TERT promoter activation is induced by HDAC inhibition is
consistent with several prior studies38, 39, 111. Furthermore, siRNA-mediated knockdown confirmed specificity for HDAC1 in the repression of TERT transcription in
VSMC. Conversely, overexpression of HDAC1 has been reported to lead to the
repression of the TERT promoter in cancer cells39. However, the regulation of
TERT by histone deacetylation remains controversial, since TERT transcription
has also been reported to be repressed by pharmacological HDAC inhibitors40, 114.
Therefore, the mechanisms underlying TERT transcription are likely dependent on
the environmental cues and specific for various tissues.
Although Scriptaid treatment of VSMC activated the promoter, TERT activity
was reduced and TERT protein degradation enhanced by HDAC inhibition. In
addition to activating transcription by histone tail modification, HDAC inhibitors are
well-established to induce post-translational modification, including protein
degradation through ubiquitination115,

116.

Moreover, while TERT expression is

primarily regulated at the transcriptional level, posttranslational modification and
proteasome-mediated degradation of TERT have been reported to play an
important role for telomerase inactivation117,

118.

In support of a differential

regulation of TERT transcript levels and protein abundance by HDAC inhibition is
a recent study in glioma cells that reported decreased TERT activity albeit
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increased TERT transcription in response to HDAC inhibition119. The molecular
mechanism underlying enhanced TERT protein degradation by HDAC inhibition is
likely indirect through increased lysine acetylation of non-histone proteins, thereby
regulating protein stability. One reasonable hypothesis supported by the literature
for future investigation may involve increased acetylation of the TERT chaperone
HSP90 by HDAC inhibition120, an effect that would result in enhanced protein
degradation of its well-established client TERT117.
HDAC inhibitors target TERT expression in cancer cells40,

121

and have

recently provided promising results in phase II clinical trials122, 123; however, their
efficacy in human vascular disease remains unknown. In preclinical models, HDAC
targeting stabilizes atherosclerosis and prevents proliferative remodeling during
neointima formation following endovascular injury100, 101. In this study, we extend
these observations and demonstrate that HDAC inhibition downregulates TERT
expression during neointima formation in vivo. Specific targeting of telomerase
activity in a rat model of vascular injury has recently been demonstrated to prevent
neointima formation124. Furthermore, TERT depletion is well-established to inhibit
VSMC proliferation and induce cellular senescence30,

31,

consistent with our

observation that Scriptaid-dependent downregulation of TERT protein abundance
increased

beta-galactosidase

staining

and

senescence-associated

gene

expression. Therefore, although the inhibition of VSMC proliferation and neointima
formation by Scriptaid in our previous studies likely involves targeting of multiple
mitogenic proteins101, TERT repression may play an important role for the antiproliferative efficacy of HDAC inhibitors.

34

Figure 2.1 HDAC Inhibition Induces TERT Transcription.
A-B, Scriptaid increases TERT mRNA expression in a dose- (A) and timedependent (B) manner. TERT mRNA expression levels was analyzed by
quantitative real-time RT-PCR and normalized to transcript levels of the
housekeeping gene RPL3A. Values are mean ± SEM (* P < 0.05 vs. DMSO
treatment). C, HDAC1 siRNA increases TERT mRNA expression. VSMC were
transfected with siRNA targeting HDAC1, 2 and 3, or Scrambled siRNA control.
Values are mean ± SEM (* P < 0.05 vs. scrambled siRNA). D, Scriptaid activates
the TERT promoter. VSMC were treated with 6 µM Scriptaid or DMSO after
transfection with a TERT promoter construct driving a luciferase reporter.
Transfection efficiency was adjusted by normalizing firefly luciferase activities to
Renilla luciferase activities generated by cotransfection with pRL-CMV. Values
are mean ± SEM (* P < 0.05 vs. DMSO).
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Figure 2.2 HDAC Inhibition Decreases TERT Protein Levels and
Telomerase Activity.
A-B, Scriptaid down-regulates TERT protein expression. TERT protein
expression levels were analyzed by Western blotting in nuclear (A) and
cytoplasmic (B) fractions harvested after 24 hours of Scriptaid or DMSO
treatment. Cohybridization for TBP or GAPDH was performed to control for equal
protein loading. The autoradiographs shown are representative of 3
independently performed experiments. C. Scriptaid decreases telomerase
activity in VSMC. Telomerase activity was analyzed 48 hours after 3 µM
Scriptaid or DMSO treatment. Values are mean ± SEM (* P < 0.05 vs. DMSO).
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Figure 2.3 HDAC Inhibition Accelerates TERT Protein Degradation.
After Scriptaid or DMSO pre-treatment, cycloheximide (CHX 10µg/ml) was
added to inhibit protein synthesis and whole cell lysates were harvested at the
indicated time points. The autoradiographs shown are representative of 3
independently performed experiments.
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Figure 2.4 HDAC Inhibition Induces VSMC Senescence.
A, Scriptaid enhances senescence-associated β-galactosidase activity.
Serum-deprived VSMC were pretreated with Scriptaid or DMSO at the
indicated doses for 30 minutes, and then stimulated with 10% FBS for 48
hours. Scale bars, 100 µM. B, Scriptaid induces senescence-associated
gene expression. mRNA was harvested 24 hours after 6 µM Scriptaid or
DMSO treatment. P16, P21, and GADD45 mRNA expression levels were
analyzed by quantitative real-time PCR and normalized to transcript levels
of the housekeeping gene RPL3A. Values are mean ± SEM (* P < 0.05 vs.
DMSO treatment).
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Figure 2.5 HDAC Inhibition Reduces TERT Expression in the
Neointima Following Vascular Injury.
A, Representative TERT staining in the neointima after vascular injury.
Tissues were stained for TERT (red) and nuclei counterstained with
hematoxylin (blue). Scale bars, 100 µM. B, Quantification of TERT-positive
cells in the neointima. The percentage of TERT-positive cells to the
neointima area was calculated as the amount of TERT-positive cells
divided by the neointima area. Cross sections with the same distance from
sutures were examined (n= 3 per group). Values are mean ± SEM (* P <
0.05 vs. DMSO treatment).
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3

CHAPTER THREE

Telomerase Reverse Transcriptase Deficiency Prevents
Neointima Formation
Through Chromatin Silencing of E2F1 Target Genes

3.1

Abstract

Objective: Aberrant proliferation of smooth muscle cells (SMC) in response to
injury induces pathological vascular remodeling during atherosclerosis and
neointima formation. Telomerase is rate limiting for tissue renewal and cell
replication; however, the physiological role of telomerase in vascular diseases
remains to be determined. The goal of the present study was to determine whether
telomerase reverse transcriptase (TERT) affects proliferative vascular remodeling
and to define the molecular mechanism by which TERT supports SMC
proliferation.
Approach and Results: We first demonstrate high levels of TERT expression in
replicating SMC of atherosclerotic and neointimal lesions. Using a model of guidewire induced arterial injury, we demonstrate decreased neointima formation in
TERT-deficient mice. Studies in SMC isolated from TERT-deficient and TERT
overexpressing mice with normal telomere length established that TERT is
necessary and sufficient for cell proliferation. TERT-deficiency did not induce a
senescent phenotype but resulted in G1 arrest albeit hyperphosphorylation of the
retinoblastoma protein. This proliferative arrest was associated with stable
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silencing of the E2F1-dependent S phase gene expression program and not
reversed

by

ectopic

overexpression

of

E2F1.

Finally,

chromatin

immunoprecipitation and accessibility assays revealed that TERT is recruited to
E2F1 target sites and promotes chromatin accessibility for E2F1 by facilitating the
acquisition of permissive histone modifications.
Conclusions: These data indicate a previously unrecognized role for TERT in
neointima formation through epigenetic regulation of proliferative gene expression
in SMC.

3.2

Introduction
Telomerase has been implicated in multiple developmental processes

including cell activation, differentiation, proliferation, and apoptosis43. The catalytic
activity of

telomerase

maintains telomeres,

hexanucleotide DNA-protein

complexes that protect the ends of chromosomes, and is rate-limiting for tissue
renewal125. Since most somatic cells repress the telomerase reverse transcriptase
(TERT) catalytic core, telomeres shorten progressively during tissue renewal
ultimately limiting lifespan91. In addition to the extension of telomeres, mounting
evidence suggests that TERT exhibits a direct regulatory role in the activation of
gene expression without apparent involvement of its well-established function in
telomere homeostasis126. Early profiling experiments first documented that TERT
induces differential gene expression55. More recent support for a non-canonical
activity of TERT derives from the observation that TERT induces cell proliferation
independently of its catalytic activity and function to elongate telomeres 55, 94, 127-129.
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Although the mechanisms underlying this non-canonical, mitogenic function of
TERT remain elusive, TERT has been demonstrated to activate specific
transcriptional programs and associates with chromatin at locations distant to
telomeres, indicating a possible function of TERT in the epigenetic control of gene
expression60, 130.
Aberrant cell proliferation constitutes an important mechanism underlying
proliferative vascular remodeling during atherosclerosis and neointima formation2.
Although telomerase is recognized as one of the most ancestral proteins in the
control of mammalian cell proliferation, it remains to be investigated whether TERT
causally contributes to these cardiovascular diseases. TERT expression is low in
quiescent SMC of the normal vasculature71,

78,

formation and atherosclerosis development30,

but increased during neointima

70, 71.

In cultured cells, TERT is

induced in both activated macrophages and in proliferating SMC30, 70, 71, 98. In SMC,
the transient increase in TERT abundance in response to growth factor stimulation
serves a mitogenic role since inhibition of TERT by oligonucleotide or
pharmacological targeting inhibits SMC proliferation30, 31, 70, 75, 98, 131. Furthermore,
acute telomerase downregulation using TERT antisense RNA decreases
proliferation of SMC isolated from genetically hypertensive rats132. Although recent
genetic experiments established that the mitogenic activity of TERT requires
neither telomere extension nor the catalytic activity55,

127-129,

the molecular

mechanisms by which TERT supports cellular proliferation remain elusive.
In this study, we employed a genetic model of TERT-deficiency to
investigate the transcriptional mechanisms underlying the mitogenic activity of
42

TERT during proliferative vascular remodeling. Our studies reveal that TERT
deletion prevents neointima formation and SMC proliferation by inducing a
silenced chromatin environment at S phase gene promoters.

3.3

Materials and Methods

Immunohistochemical Staining
For immunohistochemical staining of TERT expression in human coronary
atherosclerotic lesions, segments of coronary arteries were harvested from
explanted hearts during cardiac transplantation as described71. Tissues were fixed
in 4% phosphatebuffered formaldehyde and embedded in paraffin, and transverse
sections (8 μm) were collected. Serial paraffin-embedded sections were incubated
with a mouse monoclonal TERT antibody (ab5181, Abcam) or mouse monoclonal
anti-smooth muscle α-actin antibody (ab18147, Abcam) followed by biotinylated
goat anti-mouse IgG (BA-9200, Vector Laboratories) and counterstaining with
hematoxylin. For immunofluorescent colocalization studies, tissues were
incubated with antibodies raised against TERT (GTX82476, GeneTex), PCNA
(ab2426, abcam) and a-SMA (ab7817, abcam), followed by incubation with Alexa
Fluor 647-conjugated goat anti-chicken, Alexa Fluor 488-conjugated goat antimouse, and Alexa Fluor 594-conjugated goat anti-rabbit antibodies (A-21449,
A11001 & A11012, Invitrogen) and counterstaining with DAPI. Using a similar
protocol, paraffin-embedded sections of mouse femoral arteries subjected to guide
wire-induced injury or sham surgery were stained with PCNA (ab18197, abcam)
or TERT (MA5-16034, Thermo) followed by incubation with Alexa Fluor 48843

conjugated goat anti-mouse and Alexa Fluor 594-conjugated goat anti-rabbit
antibodies (A11001 & A11012, Invitrogen) and counterstaining with DAPI.

Cell Culture
Primary human coronary artery SMC and growth media were commercially
obtained (Lonza) and cultured per the manufacturer’s instructions. Primary murine
aortic vascular SMC were isolated from mice as described. TERT-/- mice were
obtained from The Jackson Laboratory (TERT-/- mice133, stock number 005423,
The Jackson Laboratory) and maintained using heterozygote parental breeders57.
SMC were isolated from the first generation offspring littermate G1TERT+/+ and
G1TERT-/- mice. To obtain third generation G3TERT-/- offsprings, G1TERT-/mice were interbreed using cousin mating strategies. Mice overexpressing a
murine TERT transgene (referred to as TERTtransgenic) under control of the
ubiquitin C promoter were kindly provided by Drs. Richard Hodes and Jeffrey
Chiang133. Mice hemizygous for this transgene were interbred with C57BL/6J mice
obtained from the Jackson Laboratory (C57BL/6J, Stock number 000664, The
Jackson Laboratory) to generate littermate TERT wildtype mice (referred to as
TERTwildtype). For all cell culture experiments, cells passage three to nine were
used. Cells were grown to 60-70% confluence and serum deprived in 0.4% FBS
(Invitrogen) for at least 24 hours, followed by stimulation with 10% FBS for the
indicated time. All human and animal studies were performed with the approval of
the University of Kentucky, Institutional Review Board or Institutional Animal Care
and Use Committee, respectively.
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TERT siRNA Transfection
siRNA experiments were performed using the SMARTpool technology
(Dharmacon RNA Technologies), which provides a mix of four different proprietary
siRNAs specific for human TERT. Human coronary artery SMC were transfected
with TERT or scrambled siRNA (50 nM) using LipofectamineTM RNAiMAX
(Invitrogen) for 6 hours.

Adenoviral Infection
Human coronary artery SMC, or G1TERT+/+ and G1TERT-/- SMC were
transduced with the indicated plaque-forming units (PFU)/cell of adenovirus
overexpressing GFP (Adx-GFP), TERT (Adx-TERT/GFP), or E2F1 (Adx-E2F1).
Transduction efficiency was verified at > 90% using fluorescence microscopy and
Western Blotting. For 5-bromodeosyuridine incorporation (BrdU) assays, SMC
were incubated with BrdU reagent for 12 hours after 24-hours of adenoviral
infection.

Proliferation Assays
For all proliferation assays, cells were serum-deprived for 24 hours and
stimulated with 10% FBS for 48 hours. SMC proliferation was analyzed by cell
counting using a hemocytometer. BrdU assays (Millipore) were performed per
manufacturer’s instructions. For analysis of cell cycle distribution, cells were
trypsinized, fixed in ice cold 70% ethanol, treated with 40 μg/mL RNase (in PBS)
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for 30 minutes at 37°C, and labeled with 50 μg/mL propidium iodide (in PBS). Cell
cycle distribution was determined using a FACSCalibur sorting system (Becton
Dickinson). For all data shown, individual experiments were performed at a
minimum in triplicate using different preparations of cells.

Endovascular Femoral Artery Guidewire Injury
Guidewire-induced endothelial denudation injuries were performed on the
left femoral artery of littermate G1TERT+/+ and G1TERT-/- mice (n=8/group) at 812 weeks of age with a 0.25-mm SilverSpeed-10 hydrophilic guidewire (Micro
Therapeutics Inc, Irvine, Calif) as described134. The denudation injury was
accomplished with 4 passages of the wire. Mice were euthanized 28 days after
injury, and femoral arteries were isolated and embedded in paraffin for tissue
analysis. Sections were stained with an elastic Verhoeffvan Gieson staining kit
(Sigma Aldrich) to visualize the internal and external elastic lamina. The intimal
and medial areas were measured by computerized morphometry using Image-Pro
Plus 7.0 software (MediaCybernetics) as described134.

Western Blotting
Western blotting was performed as previously described 134 using the
following antibodies: Phospho-Rb (Ser807/811) (9308, Cell Signaling), MCM7 (sc9966, Santa Cruz Biotechnology), Acetyl-Histone H3 (Lys9) (9469, Cell Signaling),
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TERT (600-401-252, Rockland), E2F1 (05-379, Upstate), CBP (7389, Cell
Signaling) and GAPDH (sc-25778, Santa Cruz Biotechnology).

Quantitative RT-PCR
RNA isolation and quantitative real-time RT-PCR analyses were performed
as recently described. Primer sequences are listed in Table I. mRNA expression
levels were analyzed in triplicate and normalized to housekeeping genes TFIIB
(murine) or TBP (human). For quantitative real-time RT-PCR analyses, data were
calculated using the 2-ΔΔCt method102.

Immunoprecipitation
Human coronary artery SMC extracts were immunoprecipitated overnight
with 2 µg rabbit IgG (2729, Cell Signaling), anti-TERT (600-401-252, Rockland),
or anti-E2F1 (sc-193, Santa Cruz), followed by 4 hours incubation with protein A
agarose beads (9863, Cell Signaling). The protein A-antigen-antibody complexes
were washed five times with 1 x cell lysis buffer, resuspended with 3x SDS sample
buffer, and heated at 100°C for 5min. Samples were then analyzed by Western
Immunoblotting with indicated antibodies.

TERT shRNA Lentiviral Transduction
SMARTvector human lentiviral TERT shRNA (5548171, GE Dharmocon)
was employed to deplete TERT expression (referred to as shTERT). SMARTvector
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empty vector control (S-005000-01, GE Dharmocon) was used as negative control
(referred to as shCTL). Human coronary artery SMC were infected with lentivirus
at an MOI of 5 for 24 hours. Infection efficiency was verified at >90% after 48 hours
infection by mRNA quantification using real-time PCR.

Chromatin Immunoprecipitation Assays
SMC were stimulated with FBS for 10 hours following 24 hours of serumdeprived starvation. Cells were then collected for Chromatin Immunoprecipitation
(ChIP) assays using the MAGnify Chromatin Immunoprecipitation System
(Invitrogen) according to manufacturer’s instructions. 50μg of chromatin was
immunoprecipitated with 5μg of antibody raised against E2F1 (sc-193x, Santa
Cruz Biotechnology), TERT (582000, Calbiochem), Acetyl-Histone H3 (Lys9)
(9649, Cell Signaling) or CBP (7389, Cell Signaling). Rabbit polyclonal IgG
(Invitrogen) was used as a negative control. Immunoprecipitated DNA was
amplified by quantitative RT-PCR using SYBR green. Primers used for quantitative
PCR amplify nucleotides -346 to -176bp of the murine MCM7 promoter, -356 to 102bp of the murine cyclin A promoter, -305 to -97bp of the murine PCNA
promoter, -355 to -190bp of the human MCM7 promoter, -250 to -100bp of the
human cyclin A promoter, and -547 to -700bp of the human PCNA. In addition,
primers targeting loci upstream of E2F1 binding sites were used as negative
controls. Primer sequences are listed in Table I.
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Chromatin Accessibility by Real-Time PCR (ChART-PCR)
G1TERT+/+ and G1TERT-/- SMC were serum-deprived and stimulated with
FBS for 12 hours. Following stimulation, nuclei were harvested using the protocol
described by Rao et al.

135and

digested using Cac8I restriction enzyme (New

England BioLabs). Digested DNA was purified using the QIAquick Gel Extraction
Kit (QIAGEN) per manufacturer’s instructions. 20ng of recovered DNA was
analyzed by quantitative PCR using SYBR green. Primers used amplify
nucleotides -346 to -176bp of the murine MCM7 promoter and encompass two
E2F1 binding sites and three Cac8I restriction sites. Decreased PCR amplification
of this sequence indicates Cac8I digestion and increased chromatin accessibility.
Results were normalized using primers which amplify upstream sequences - 620
to -513bp of the murine MCM7 promoter lacking Cac8I restriction sites (listed in
Table I) and expressed as percent accessibility.

Telomere Length Analysis
For quantification of telomere length using real-time PCR, samples were
run in triplicate with 35 ng of DNA per reaction using an iCycler and SYBR Green
I system (Bio-Rad) as described. Telomere repeat copy number data were
normalized to 36B4 as single-copy gene. The primer sequences are listed in Table
I.
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Senescent Staining
Murine SMC were seeded at a density of 8x105 cells per well on a 6-well
plate and serum-deprived in DMEM containing 0.4% FBS. After 24 hours,
senescent staining was performed as previously described using the Senescent
Cells Histochemical Staining Kit (Sigma Aldrich).

Statistical Analysis
To compare two groups on a continuous response variable, we used a 2sample Student t test or Mann–Whitney U test as appropriate. One-way ANOVA
was used to compare multiple groups, followed by Tukey post hoc analysis. All
data are presented as mean ± SEM.

3.4

Results

3.4.1 TERT Is Expressed in Replicating Neointimal Smooth Muscle Cells
TERT protein expression was first analyzed in neointimal SMC of human
coronary artery atherosclerotic lesions from hearts explanted during cardiac
transplantation. While TERT expression is considered negligible in normal
arteries71, 78, we confirmed abundant TERT expression in the SMC-rich neointimal
region of the fibroatheroma (Figure 3.1 A). Furthermore, confocal microscopy
confirmed that TERT expression colocalizes with proliferating cell nuclear antigen
(PCNA), a cofactor of DNA polymerase required for replication (Figure 3.1 B).
Similarly, TERT was highly expressed in replicating SMC during the proliferative
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response following vascular injury of the mouse femoral artery (Figure 3.1 C).
Therefore, this upregulation of TERT expression may indicate an important role in
vascular remodeling underlying neointima formation.

3.4.2 TERT Is Required for Smooth Muscle Cell Proliferation and
Neointima Formation
Inhibition of TERT has previously been shown to inhibit SMC proliferation 75,
98, 131.

Using siRNA-mediated TERT knock-down and adenoviral-mediated

overexpression of TERT (Appendices Figure A.1A-C), we corroborated that TERT
is both necessary and sufficient for SMC proliferation (Figure 3.2 A-B). To advance
these studies to in vivo models, we next isolated primary aortic SMC from TERTdeficient and TERT overexpressing mice133. Consistent with the well-described
phenotype26,

136-138,

the first generation G1TERT-/- progeny from heterozygote

founder mice exhibits normal telomere length (Appendices Figure A.2) and none
of the phenotypes associated with telomere attrition. However, homozygous
intercrossing of G1TERT-/- mice results in progressive telomere loss in third
generation G3TERT-/- mice (Appendices Figure A.2). To further complement this
genetic TERT depletion model, we studied proliferation of SMC isolated from
C57BL/6 mice overexpressing a murine TERT transgene under control of the
ubiquitin C promoter (referred to as TERTtransgenic)133. When exponentially
growing aortic SMC from these mice were analyzed (Figure 3.2 C), cells isolated
from hemizygous TERTtransgenic mice displayed a marked growth advantage
compared to their littermate controls (referred to as TERTwildtype). Conversely,
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SMC isolated from G1TERT-/- mice exhibited a complete growth arrest compared
to G1TERT+/+ cells. Interestingly, the growth arrest occurred to a similar extent in
G1 and G3TERT-/- SMC, indicating that this mitogenic defect is primarily due to
TERT deletion and does not require telomere attrition. To further corroborate that
the mitogenic arrest is due to TERT deficiency, we overexpressed TERT in
G1TERT-/- SMC, which rescued proliferation (Figure 3.2 D). Based on these data
and to investigate the regulation of SMC proliferation by TERT in vivo, we next
analyzed the proliferative response underlying neointima formation in G1TERT-/mice. As depicted in Figure 3.3 A and B, neointima formation was significantly
decreased in G1TERT-/- mice compared to their wildtype G1TERT+/+ littermates.
Collectively, these results indicate that TERT deletion decreases SMC proliferation
in vitro and during neointima formation in vivo.

3.4.3 TERT Deletion Induces Cell Cycle Arrest and Silences E2F1 Target
Gene Expression
We next sought to identify the mechanisms responsible for the growth arrest
of G1TERT-/- SMC. Using real-time PCR for sensitive quantification of telomere
lengths, we first confirmed that G1TERT-/- SMC did not display measurable
evidence of telomere attrition (Appendices Figure A.2). Furthermore, TERT
deficiency did not induce senescence-associated β-galactosidase staining or gene
expression (Appendices Figure A.3 A-B). From these data we inferred that the
growth arrest induced by TERT-deficiency was likely independent of the wellestablished function of TERT to extend telomeres and prevent cellular
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senescence. Therefore, we next analyzed DNA synthesis and cell cycle
distribution. These studies revealed that TERT deficiency inhibited mitogeninduced DNA synthesis (Figure 3.4 A) and arrested SMC in the G0/G1 phase of the
cell cycle to reduce S phase entry (Figure 3.4 B-C). This transition from G1 → S
phase is mediated through phosphorylation of the retinoblastoma protein (Rb) 139.
However, TERT depletion did not result in decreased Rb phosphorylation but
rather hyperphosphorylation (Figure 3.4 D-E), indicating that TERT deletion alters
DNA synthesis likely through a mechanism downstream of Rb phosphorylation.
Rb phosphorylation releases the transcription factor E2F1, which
transactivates promoters required for S phase entry and ensuing DNA replication,
including the bona fide E2F1 target genes cyclin A, PCNA, and minichromosome
maintenance proteins (MCM)140,

141.

Although Rb was hyperphosphorylated in

G1TERT-deficient cells, downstream expression of these three E2F1 target genes
was silenced (Figure 3.4 F). This differential S phase gene expression profile
occurred in the absence of changes in E2F1 expression levels (Appendices Figure
A.4). Similarly, other activating E2F family members were not affected by deletion
of the TERT locus (Appendices Figure A.3.B). To further complement this finding,
we employed siRNA-mediated knockdown of TERT in primary human coronary
artery SMC. As depicted in Figure 3.4 G-I, the induction of MCM7 mRNA and
protein expression in response to mitogenic stimulation was attenuated in TERTdepleted SMC. Complementary data was obtained for the E2F1 target genes cyclin
A and PCNA (data not shown).
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3.4.4 TERT Is Recruited to Chromatin and Required for E2F1 Binding to
Canonical Sites
The silencing of E2F1 target gene expression in TERT-deficient SMC
indicated that TERT might facilitate E2F1-dependent transcription. To assess this
possibility, we first confirmed that E2F1 and TERT physically associate in human
coronary artery SMC (Figure 3.5 A). However, to more directly test whether TERT
is

recruited

to

canonical

E2F1

motifs,

we

performed

chromatin

immunoprecipitation (ChIP) assays using primer pairs that cover the E2F1 sites in
the cyclin A, PCNA, and MCM7 promoters. As shown in Figure 3.5 B, mitogenic
stimulation of G1TERT+/+ SMC induced not only E2F1 binding to its target site in
the MCM7 promoter but also a potent and inducible co-recruitment of TERT.
Further evaluation of the chromatin complex demonstrated that this recruitment of
E2F1 and TERT was associated with increased acetylation of histone H3 (K9AcH3), a typical chromatin modification of gene activation142. To investigate whether
TERT is required for E2F1 binding to chromatin and to validate the role of TERT
in the regulation of E2F1-dependent transcription, we next analyzed whether TERT
deficiency affects E2F1 recruitment to its response elements within the MCM7,
Cyclin A, and PCNA promoters. As depicted in Figure 3.5 C, inducible TERT
binding to E2F1 canonical sites in the MCM7 promoter was negligible in human
coronary artery SMC depleted of TERT using a lentiviral approach (Appendices
Figure A.1 D). Similarly, no TERT binding was observed at upstream noncanonical promoter regions (Appendices Figure A.6), confirming specificity of the
ChIP assay. Comparable results were observed for the cyclin A and PCNA
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promoters (data not shown). As further shown in Figure 3.5 D-F, this mitogeninduced E2F1 recruitment to the MCM7, cyclin A, and PCNA promoters was
significantly reduced upon TERT depletion. A complementary impairment of E2F1
binding to its target sites was observed in G1TERT-/- murine cells (data not
shown). These studies confirm that TERT supports E2F1 binding to its target sites
within promoters of genes required for entry into S-phase of the cell cycle.

3.4.5 TERT-Deficiency Decreases Chromatin Accessibility and Histone
Acetylation
We next examined chromatin accessibility specifically at E2F1 binding sites
using a Chromatin accessibility by Real-Time PCR (ChART-PCR) assay135. Briefly,
this highly sensitive assay to quantify chromatin accessibility combines DNase
hypersensitivity with specific restriction enzyme digestion followed by PCR
amplification, thereby providing a quantitative chromatin accessibility assessment
at a specific transcription factor binding site. Genomic DNA from G1TERT-/- and
G1TERT+/+ SMC was subjected to DNase I, meningococcal nuclease, and Cac8I
restriction enzyme digestion followed by real-time PCR using primers
encompassing the E2F1 motif in the MCM7 promoter (Figure 3.6 A). The restriction
enzyme Cac8I specifically cleaves the E2F1 motif TTTCGCGC, and accessible
euchromatin will not be amplified by PCR since the primers cannot hybridize to the
E2F1 site due to cleavage by the restriction enzyme. As shown in Figure 3.6 B,
TERT-deficiency was associated with significantly reduced chromatin accessibility
at the E2F1 site relative to G1TERT+/+ SMC. Since our data established that
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TERT occupancy of E2F1 sites is associated with the enrichment of histone H3
acetylation, we further analyzed whether TERT-deficiency modulates the
recruitment of permissive histone acetylation at E2F1 sites. As shown in Figure 3.6
C, FBS stimulation of human coronary artery SMC resulted in a profound increase
in lysine 9 histone H3 acetylation of the E2F1 response elements within the MCM7
promoters. In contrast, this inducible histone acetylation was completely abolished
in human coronary artery SMC transduced with TERT shRNA lentivirus. Similarly,
mitogen-induced lysine 9 histone H3 acetylation was reduced at the protein level
in G1TERT-/- SMC (Figure 3.6 D-E), a finding that may at least in part contribute
to the silenced chromatin state at E2F1 sites in TERT-deficient cells. Considering
that the p300/CREB-binding protein (CBP) coactivator family confers histone
acetyltransferase activity41 that is required for E2F1 activation of its S phase target
genes42, we investigated whether CBP contributes to histone H3 acetylation during
TERT-dependent E2F1 recruitment. A direct TERT-CBP interaction was first
confirmed by immunoprecipitation (Figure 3.6 F). Furthermore, mitogen-induced
CBP recruitment to E2F1 target chromatin within the MCM7 promoter was
confirmed by ChIP. In contrast, inducible CBP recruitment was markedly impaired
upon TERT deletion (Figure 3.6 G). Decreased H3 acetylation and altered CBP
recruitment upon TERT depletion were also observed at the cyclin A and PCNA
(data not shown). These findings suggest that TERT facilitates CBP recruitment
and subsequent Histone H3 acetylation to disrupt repressive chromatin at E2F1
target chromatin.
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To finally corroborate decreased chromatin accessibility as a possible
mechanism underlying silencing of E2F1 target genes, we overexpressed E2F1 in
G1TERT-/- SMC. A silenced chromatin state accompanying TERT deficiency
should produce a permanent insensitivity to E2F1-dependent proliferation, since
E2F1 would be unable to access its consensus sites. As depicted in Figure 3.6 HJ, adenoviral-mediated transduction of E2F1 (Appendices Figure A.5) in SMC
wildtype for the TERT locus increased expression of its target gene MCM7
expression and the ensuing cell proliferation and DNA synthesis. In contrast, this
activity of ectopic E2F1 to induce target gene transcription and cell proliferation
was altered in TERT-deficient SMC. Collectively, these experiments identify TERT
as a component of the chromatin complex at E2F1 sites and establish a previously
unrecognized role for TERT to activate E2F1-dependent gene promoters through
chromatin modulation.

3.5

Discussion
Altered SMC function constitutes a pivotal component of pathological

vascular remodeling and neointima formation2,

143.

In the present study, we

illustrate a previously unrecognized mechanism that supports the mitogenic
phenotype of SMC. The inducible expression of TERT in proliferating SMC during
vascular remodeling and the requirement for SMC proliferation in vitro and
neointima formation in vivo establish an important role for TERT in vascular
biology. TERT is required for the activation of an S phase gene expression
program, associates with chromatin at E2F1 consensus sites, and facilitates the
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acquisition of a permissive chromatin environment through CBP-mediated histone
acetylation. Collectively, these experiments support a novel role for TERT in the
epigenetic control of SMC proliferation.
While expression of the catalytic subunit of telomerase TERT is considered
to be negligible in the normal vasculature71, 78, we observed that TERT is induced
in proliferating SMC during the neointimal remodeling process resulting from
atherosclerosis formation or vascular injury. Using loss and gain-of-function
approaches combined with genetic TERT modulation in mice, our data
demonstrate a causal relationship between TERT expression and the mitogenic
response. Similarly, prior studies using oligonucleotide or pharmacological
targeting of TERT documented decreased SMC proliferation75, 98, 131. To extend
these observations, we studied SMC proliferation in primary cells isolated from
G1TERT-deficient mice in vitro and neointima formation in vivo in mice deficient
for the TERT locus. This murine model has been widely employed to exploit
telomere-independent functions of TERT in G1TERT-/- mice with normal telomere
lengths as well as phenotypes that occur as a result of progressive telomere
attrition in third generation G3TERT-/- mice131,

144-147.

Conversely, constitutive

expression of TERT in transgenic mice does not elongate telomeres136 since TERT
only elongates critically short telomeres57,

148.

Therefore, this transgenic model

provides another means to study TERT activities that occur independently of its
function to extend telomeres94, 127-129. In our experiments, TERT-deficiency in the
presence of normal telomere length in G1TERT-/- mice induced growth arrest of
SMC and reduced neointima formation. In contrast, TERT overexpression in SMC
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isolated from transgenic mice elicited a clear growth advantage. From these
observations we infer that the SMC growth arrest induced by TERT deficiency
does not depend on telomere attrition but rather on TERT function. Consistent with
this notion is the accumulating evidence that TERT induces, for example, stem cell
and cancer proliferation through telomere-independent mechanisms that do not
require the catalytic activity94,

127-130.

Furthermore, proliferating cancer cells

express splice variants deficient in catalytic activity, and expression of these
variants in telomerase-negative cells induces cell proliferation149, pointing to a
novel non-canonical function of TERT in the regulation of cell proliferation.
G1TERT-deficient SMC did not display senescence-associated changes in
their phenotype or gene expression, further supporting a telomere-independent
mechanism of growth arrest. Instead, cell cycle analysis revealed that TERTdeficiency induced a G1S phase arrest associated with decreased DNA
synthesis. Similarly, acute knock-down of TERT in cancer cells induces cell cycle
arrest without telomere shortening while TERT overexpression drives epithelial
cells into S phase150, 151. In proliferating cells, phosphorylation of the Rb protein
constitutes a critical first step for S phase entry139, which in turn releases its active
transcriptional repression of E2F1139,

141.

In TERT-deficient SMC we observed

hyperphosphorylation of Rb, which would be expected to release E2F1-dependent
repression, induce target gene transcription, and facilitate S phase entry. Contrary
to this assumption, mitotic E2F1 target genes required for DNA synthesis were
silenced in TERT-deficient SMC, albeit increased Rb phosphorylation. This
unanticipated requirement of TERT for E2F1-dependent transcription was neither
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the result of decreased E2F1 protein expression nor reversible by ectopic E2F1
overexpression, indicating a stable transcriptional silencing in response to TERT
deletion that cannot be attributed to a lack of E2F1 availability. Alternatively, a
model in which E2F1 is present but unable to gain access to cognate binding sites
due to condensed chromatin in TERT-deficient SMC appears conceivable. The
ensuing altered transcription of E2F1-dependent genes in turn may provide a
positive feedback to mechanisms that are upstream of Rb and induce its
phosphorylation to overcome the proliferative arrest. Consistent with this concept
is our observation that altered expression of E2F1 target genes in TERT-deficient
SMC is associated with decreased E2F1 binding to their respective consensus
motifs. To our knowledge these are the first data to demonstrate that E2F1dependent activation of S phase genes requires TERT expression. These findings
complement the more widely appreciated function of telomerase in maintaining
telomere repeats and provide a molecular mechanism underlying the welldescribed, mitotic function of TERT.
Using ChIP assays, we demonstrate that TERT is recruited along with E2F1
to consensus sites within differentially regulated target genes. This inducible TERT
occupancy of E2F1 sites is associated with the enrichment of CBP and permissive
histone H3 acetylation on lysine 9 (K9Ac-H3). To confirm that TERT recruitment to
E2F1 cognate elements is functionally important for the activation of chromatin, we
probed for acetylated histone marks and chromatin accessibility. These studies
revealed that TERT deletion decreases histone acetylation at E2F1 sites and
reduces chromatin accessibility at the E2F1 site. Therefore, it is unlikely that the
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mechanism by which TERT activates E2F1-target promoters is through direct DNA
binding but rather involves chromatin remodeling and/or facilitated recruitment of
other chromatin-modifying enzymes. CBP supports histone acetyltransferase
activity required for E2F1 binding152. Our observations support that the association
of TERT with CBP facilitates its recruitment to chromatin and local histone
acetylation, which releases repressive chromatin. This hypothesis is further
supported by the recent finding that TERT regulates Wnt-dependent transcription
in stem cells through chromatin association and interaction with the chromatin
modifier BRG160. BRG1 constitutes the energy-providing subunit of multiple
chromatin-modifying enzymatic complexes to disrupt the chromatin architecture of
target promoters and recruit histone acetyltransferases, which represent critical
steps for E2F1-induced promoter activation152. Considering our observation that
TERT depletion decreased chromatin accessibility and histone acetylation at E2F1
sites, it is possible that TERT serves as a chaperone to facilitate the recruitment
of BRG1 and/or histone acetyltransferase activity to E2F1 target sites. In addition
to this mechanism, TERT has been reported to stabilize transcription factors
through inhibition of ubiquitination153. However, since E2F1 protein levels were
unaffected by TERT deletion we would consider this mechanism unlikely to explain
the chromatin remodeling of TERT-deficient SMC.
Based on our data, we conclude that transient re-expression of TERT during
cell cycle progression provides a mechanism for the transcription of S phase cell
cycle-regulatory genes. TERT is recruited to canonical E2F1 target genes and
induces a permissive chromatin environment. In vivo, this mechanism is required
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for the proliferative response of SMC to induce neointima formation. Further
investigation of this novel epigenetic function of TERT and characterization of
TERT-regulated gene expression programs will likely yield new insights into how
TERT functions as a regulator of cell proliferation.
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Figure 3.1 TERT is Expressed in Replicating Smooth Muscle Cells.
A, Expression of TERT in SMC of human coronary artery atherosclerotic lesions.
Sections of an early stage, SMC-rich fibroatheroma of a human coronary artery
were immunostained for TERT and α-smooth muscle actin. Low resolution
images (100X) and high resolution image (1000X) of the boxed area showing
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TERT staining. B, Co-localization of TERT and PCNA in SMC of atherosclerotic
lesions.

TERT

expression

in

proliferating

SMC

was

detected

by

immunofluorescence staining of TERT (white), PCNA (red), and a-SMA (green)
with nuclei counterstained with DAPI (blue) in sections of atherosclerotic
coronary arteries compared with normal controls. Scale bar 100µM. C, Coexpression of TERT and PCNA in the murine neointima following guide wireinduced femoral artery injury. Tissues were stained for TERT (green), PCNA
(red),

and

nuclei

counterstained

with

DAPI

(blue).

Representative

immunofluorescence staining of TERT and PCNA expression within injuryinduced neointima or sham arteries. Scale bar 50µM.
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Figure 3.2 TERT is Required for Smooth Muscle Cell Proliferation.
A, siRNA-induced TERT knockdown decreases SMC proliferation. Human
coronary artery SMC were transfected with TERT siRNA and serum-deprived
for 24 hours. Synchronized cells were then stimulated with FBS for 48 hours
and counted using a hemocytometer. Cell numbers are presented as mean ±
SEM relative to quiescent cells (#P<0.05 versus quiescent, *P<0.05 versus
scrambled). B, Adenoviral-mediated overexpression of TERT promotes SMC
proliferation. Serum-deprived human coronary artery SMC were transduced
for 24 hours with 100 plaque-forming units (PFU) of adenoviral constructs
overexpressing GFP/TERT (Adx-TERT/GFP) or GFP (Adx-GFP) as control.
Following transduction, proliferation was analyzed after 48 hours by cell
counting using a hematocytometer. Data are presented as mean ± SEM
relative to quiescent GFP-infected cells (*P<0.05 versus Adx-GFP). C,
Proliferation

of

vascular

SMC

isolated

from

TERT

overexpressing

(TERTtransgenic), littermate wildtype (TERTwildtype), first generation
G1TERT-/-, littermate wildtype G1TERT+/+, and third generation G3TERT-/mice (n=8 mice per group). Serum-deprived SMC were stimulated with FBS
and counted at the indicated time points using a hemocytometer. Data are
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presented as mean ± SEM (*P<0.05 versus the respective wildtype control
mice). D, TERT overexpression rescues the mitogenic defect of TERTdeficient SMC. Murine SMC from G1TERT-/- or G1TERT+/+ mice were
infected with 100 PFU of Adx-TERT/GFP or Adx-GFP. Forty-eight hours after
transduction,

proliferation

was

analyzed

by cell

counting

using

a

hematocytometer. Values are fold increase relative to G1TERT+/+ transduced
by Adx-GFP and presented as mean ± SEM (#P<0.05 versus Adx-GFP,
*P<0.05 versus G1TERT+/+).
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Figure 3.3 TERT Deficiency Attenuates Neointima Formation.
A, Photomicrographs of neointima formation in the femoral arteries of
G1TERT+/+ and G1TERT-/- mice. Guide wire-induced endothelial denudation
injuries were performed and tissues harvested after 28 days (n=8 per group).
Tissues were stained using Verhoeff-van Gieson staining to visualize the
internal and external elastic lamina. Scale bar represents 0.1 mm. B, The ratio
of intima to media was calculated as the intimal area divided by the medial
area. Data are presented as mean ± SEM (*P<0.05 versus G1TERT+/+).
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Figure 3.4 TERT Deletion Induces Cell Cycle Arrest and is Required
for E2F1 Target Gene Expression.
A, TERT-deficiency decreases DNA synthesis. SMC from G1TERT+/+ or
G1TERT-/- mice were serum-deprived and stimulated with FBS. After 24
hours BrdU incorporation was quantified. Values are mean ± SEM (#P<0.05
versus quiescent, *P<0.05 versus G1TERT+/+). B-C, TERT-deficiency
induces cell cycle arrest. SMC were prepared as in A, and cell cycle
distribution was analyzed by flow cytometry following propidium iodide
staining. The percentages of cells in G0/G1, S, and G2/M phases (B) were
calculated from flow cytometric plots of cell cycle distribution (C). Values are
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mean ± SEM (#P<0.05 versus quiescent, *P<0.05 versus G1TERT+/+).
Data were collected from three independently performed experiments (n=3
per

group).

D-E,

TERT

deletion

induces

mitogen-induced

hyperphophorylation of Rb. Cells were prepared as described in A. Whole
cell lysate was blotted for phospho-Rb (Ser 807/811) and GAPDH as loading
control. The autoradiograms shown (D) are representative of three
independently performed experiments using different cell preparations.
Densitometric quantification (E) normalized to GAPDH. Values are mean ±
SEM (#P<0.05 versus quiescent, *P<0.05 versus G1TERT+/+) F, Silencing
of S phase gene expression in G1TERT-/- SMC. SMC were stimulates with
FBS as described above. mRNA expression of MCM7, cyclin A, and PCNA
was analyzed by quantitative real-time PCR and normalized to transcript
levels of the housekeeping gene TFIIB. Values are mean ± SEM (#P<0.05
versus 0h, *P<0.05 versus G1TERT+/+ at the same time point). G-I, siRNAinduced TERT deletion suppresses MCM7 expression in human coronary
artery SMC. SMC were stimulated with FBS following transfection with
TERT siRNA or scrambled control. MCM7 transcript and protein expression
levels were analyzed by real-time PCR (G) and Western Blotting (H-I) after
12 and 24 hours, respectively. Densitometric quantification (I) normalized to
GAPDH. Values are mean ± SEM (#P<0.05 versus quiescent, *P<0.05
versus Scrambled).
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Figure 3.5 TERT is Recruited to Chromatin and Required for E2F1
Binding to Target Promoters.
A, Interaction of TERT and E2F1 in human coronary artery SMC. Cell
extracts were immunoprecipitated (IP) with control IgG or anti-E2F1
antibodies. Co-immunoprecipitated protein were visualized by Western
Blotting (WB) using anti-TERT and anti-E2F1 antibodies. B, Mitogeninduced recruitment of E2F1, TERT, and lysine 9-acetylated histone H3
(K9Ac-H3) to target chromatin of the MCM7 promoter. Representative gel
images of ChIP experiments performed in quiescent G1TERT+/+ SMC
stimulated with FBS for 10 hours. Cells were harvested for ChIP using
antibodies against E2F1, TERT, or K9Ac-H3 (indicated as IP).
Immunoprecipitation with respective non-immune IgG served as control
(indicated as IgG). Chromatin Input and non-template (NTC) are depicted
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as additional controls. The precipitated chromatin was then amplified
using primer pairs covering the E2F1 binding sites within the MCM7
promoter. C, Mitogen-induced TERT recruitment to E2F1 target
chromatin. Forty-eight hours after lentiviral transduction with either nontargeting shRNA control (shCTL) particles or TERT shRNA (shTERT)
particles, human coronary artery SMC were stimulated with FBS following
24 hour serum-free starvation and then harvested for ChIP assays.
Chromatin immunoprecipitation was performed using antibody against
TERT. Promoter binding was quantified by real-time PCR using primers
covering E2F1 binding sites within the MCM7 promoter. Cycle threshold
(Ct) values were normalized to Ct values of input samples and presented
as mean ± SEM (#P<0.05 versus quiescent, *P<0.05 versus shCTL). DF, TERT depletion abolishes mitogen-induced E2F1 binding to the
promoters of MCM7 (D), cyclin A (E), and PCNA (F). Human coronary
artery SMC were prepared as in described in (C). ChIP was performed
using anti-E2F1 antibody. Quantification of immunoprecipitated chromatin
by real-time PCR using primers covering E2F1 binding sites within the
promoter regions of MCM7, cyclin A, and PCNA. Data are presented as
mean ± SEM (#P<0.05 versus quiescent, *P<0.05 versus shCTL).
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Figure 3.6. TERT-Deficiency Decreases Chromatin Accessibility
and Histone Acetylation.
A, Schematic illustration of locations of primers, Cac8I restriction sites,
and E2F1 binding sites on MCM7 promoter. Sequences amplified by
primers (arrows), Cac8I restriction sites (-312, -244, and -182 from the
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transcription initiation site, triangles), and E2F1 binding sites (-297 and
-250 from the transcription initiation site, squares) are noted. The
transcription initiation site is marked as +1. B, TERT deletion decreases
DNA accessibility of E2F1 binding sites within the MCM7 promoter.
Nuclei isolated from FBS-stimulated SMC of G1TERT+/+ or G1TERT-/mice were digested with Cac8I restriction enzyme and purified for
ChART-PCR. Primers used for real-time PCR amplify sequences
between nucleotides -346 and -176 in the MCM7 promoter, which
encompass two E2F1 binding sites and three Cac8I restriction sites.
Results were normalized against amplification of a control sequence
upstream of the MCM7 promoter (nucleotides -620 to -513) with no
Cac8I restriction sites. Data are presented as mean ± SEM relative to
uncut samples (*P<0.05 versus G1TERT+/+). C, TERT depletion
abolishes mitogen-induced histone H3 acetylation at the E2F1
response elements within the MCM7 promoter. Human coronary artery
SMC were treated as Figure 5C. ChIP was performed using an antibody
against

acetylated

Histone

H3

(Lys9).

Quantification

of

immunoprecipitated chromatin was performed by real-time PCR using
primers covering E2F1 binding sites within the promoters of MCM7.
Data are presented as mean ± SEM (#P<0.05 versus quiescent,
*P<0.05 versus shCTL). D-E, TERT-deficiency decreases acetylation of
histone H3. Vascular SMC from G1TERT+/+ and G1TERT-/- mice were
stimulated with FBS following 24 hour serum-free starvation and protein
was harvested. Western Blotting was carried out using antibody against
acetylated Histone H3 (Lys9). Histone H3 and GAPDH were used as
loading contros. Densitometric quantification (E) normalized to H3. Data
are presented as mean ± SEM (#P<0.05 versus quiescent, *P<0.05
versus G1TERT+/+). F, Interaction of TERT and CBP in human coronary
artery SMC. Immunoprecipitation (IP) of TERT from cell lysates followed
by Western Blotting (WB) with anti-CBP. The same blot was
subsequently stripped and re-probed with anti-TERT antibody. G, TERT
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depletion reduces CBP recruitment to the E2F1 response element in
the MCM7 promoter. Human coronary artery SMC were treated as in
Figure 5C. ChIP was performed using anti-CBP antibody. Quantification
of immunoprecipitated chromatin was performed by real-time PCR
using primers covering E2F1 binding sites within the MCM7 promoter.
Data are presented as mean ± SEM (#P<0.05 versus quiescent,
*P<0.05 versus shCTL). H-J, The proliferative defect induced by TERTdeletion is not reversed by overexpression of E2F1. Vascular SMC from
G1TERT+/+ and G1TERT-/- mice were transduced with 25 PFU/cell
adenovirus overexpressing E2F1 or control GFP. MCM7 mRNA
expression was analyzed by real-time RT-PCR after 24 hours (H). Cell
proliferation was analyzed after 24 hours by cell counting using a
hemocytometer (I) or by BrdU incorporation (J). Data are presented as
mean ± SEM (#P<0.05 versus Adx-GFP, *P<0.05 versus G1TERT+/+).
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CHAPTER FOUR

Telomerase Reverse Transcriptase Deficiency
Prevents Atherosclerosis Formation through an Inhibition of
Macrophage-Related Inflammation

4.1

Abstract

Objective: Telomerase Reverse Transcriptase (TERT), the catalytic subunit of
telomerase, supports critical cellular processes required for tissue remodeling.
Previous studies established that TERT expression is induced in activated
macrophages and during experimental and human atherosclerosis formation. In
the present study, we investigated the role of TERT in atherosclerosis
development and macrophage inflammation.
Approach and Results: TERT-deficient mice were crossbred with LDL-receptordeficient (LDLr-/-) mice to generate first generation G1TERT-/-LDLr-/- offsprings,
which were then successively intercrossed to obtain the third generation G3TERT/-LDLr-/- mice. G1TERT-/-LDLr-/- mice displayed no telomere shortening while
severe telomere attrition was evident in G3TERT-/-LDLr-/- mice. When fed on an
atherogenic diet, G1TERT-/-LDLr-/- and G3TERT-/-LDLr-/- mice were both
protected from atherosclerosis formation compared to their wildtype controls,
indicating that genetic TERT-deletion prevents atherosclerosis, and formation of
the disease is not affected by telomere attrition. Similarly, atherosclerosis
development was decreased in chimeric LDLr-/- mice with TERT deletion in
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hematopoietic stem cells after bone marrow transplantation. TERT deficiency
reduced macrophage accumulation in atherosclerotic lesions and altered
chemokine expression, including CXC1/2/3, CCL3, CCL5, CCL21, CCR7, IL-6,
and IL-1α. In isolated macrophages, sequence analysis of silenced inflammatory
gene promoters indicated that TERT deletion altered signal transducer and
activator of transcription 3 (STAT3)-dependent chemokine expression and
recruitment of phosphorylated STAT3 to its target promoters. Mechanistically,
TERT

expression

was

necessary

and

sufficient

to

maintain

STAT3

phosphorylation.
Conclusions: Our data support that genetic TERT deficiency decreases
atherosclerosis formation by silencing inflammatory chemokine transcription
through inactivation of the STAT3 signaling pathway.

4.2

Introduction
Telomeres are repetitive DNA-protein complexes that protect the ends of

chromosomes and are maintained by the enzyme telomerase44. TERT confers the
catalytic activity and is the limiting factor for telomerase activation26,

110.

Overexpression of TERT in cancer and stem cells confers a virtually unlimited
replicative capacity61,

128, 154.

In contrast, most somatic cells are thought to

suppress telomerase activity by silencing the TERT gene, resulting in telomere
shortening and limited replicative potential44. While this traditional role of TERT in
maintaining telomeres is firmly established, mounting evidence points to a second
role of TERT in the control of cell signaling and gene expression that is
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independent of its reverse transcriptase activity and ability to elongate telomeres47.
For example, overexpression of TERT has been demonstrated to activate gene
transcription by chromatin modulation60. Also, multiple studies have revealed that
TERT activates various signaling pathways, including MAP-kinase89 and NF-kB
signaling58, through a telomere maintenance-independent mechanism.
Leukocyte telomere length shortens with age in humans, and telomere
dysfunction has been linked to a host of pathologies including dementia,
cardiovascular events, asthma, diabetes, and stroke43,

67.

Therefore there has

been an increasing interest in the reactivation of telomerase, the enzyme to
elongate telomeres, to protect against cellular senescence and age-related
diseases62. However, in contrast to the circulating leukocyte telomere shortening
that is generally associated with cardiovascular risk155, long telomere length69 and
telomerase activation70, 71 are observed in leukocytes isolated directly from human
unstable coronary artery plaques. Furthermore, atherosclerosis is decreased in
apoE-deficient mice with short telomeres due to lack of the telomerase component
that provides the RNA template to the enzyme84. Collectively, these results
challenge the general dogma that telomerase activation may prevent vascular cell
dysfunction and atherosclerosis development.
Considering this important function of telomerase in cell biology,
surprisingly little is known about the function of telomerase and telomere-related
molecular processes in atherosclerosis. TERT expression is thought to be
essential in preventing EC senescence72,

73.

Our laboratory has further

demonstrated that TERT is inducible in proliferating vascular smooth muscle cells
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(VSMC) and represents a mitogenic effect30, 31. Furthermore, our recent studies
confirmed

an

increased TERT

expression

in macrophages of

human

atherosclerotic lesions71, indicating a potentially important function of TERT in
vascular remodeling. However, the role of TERT in atherosclerosis has not been
investigated.

4.3

Materials and Methods

Immunohistochemical Staining
For immunohistochemical staining of TERT expression in human coronary
atherosclerotic lesions, segments of coronary arteries were harvested from
explanted hearts during cardiac transplantation as described. Tissues were fixed
in 4% phosphate-buffered formaldehyde and embedded in paraffin, and transverse
sections (8 µm) were collected. Serial paraffin-embedded sections were incubated
with a rabbit monoclonal TERT antibody (600-401-252S, Rockland) or mouse
monoclonal CD68 antibody (ab955, Abcam), followed by biotinylated goat antirabbit IgG (BA-1000, Vector Laboratories) or biotinylated goat anti-mouse IgG (BA9200,

Vector

Laboratories)

and

counterstaining

with

hematoxylin.

For

immunofluorescent colocalization studies, tissues were incubated with antibodies
raised against TERT (600-401-252S, Rockland) or p-STAT3 (9145S, Cell
Signaling), and CD68 (ab955, Abcam), followed by incubation with Alexa Fluor
488-conjugated goat anti-mouse, and Alexa Fluor 594-conjugated goat anti-rabbit
antibodies (A11001 & A11012, Invitrogen) and counterstaining with DAPI.
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Mice
Littermate TERT+/+ and TERT-/- mice on a mixed C57BL/6J background
were used (The Jackson Laboratory, Stock Number 005423). First generation
G1TERT-/- mice derived from heterozygote founder mice were further mated to
generate late generation, i.e. third generation G3TERT-/- mice. G1TERT-/- and
G3TERT-/- with their respective littermate were crossbred with male low-density
lipoprotein receptor–deficient mice (LDLr-/-, The Jackson Laboratory) to generate
G1 and G3TERT-/-LDLr-/- mice. Study mice and their littermate controls were fed
a saturated fat-enriched diet for 12 weeks to induce atherosclerosis formation
(Harlan Teklad TD.88137).
Bone marrow transplantation (BMT) was performed by repopulating lethally
irradiated male LDLr-/- mice (The Jackson Laboratory) with bone marrow–derived
cells of male first-generation TERT-deficient mice (TERT-/-, The Jackson
Laboratory, B6.129S-Terttm1Yjc/J, stock number 005423) or their wild-type
littermates (TERT+/+). Briefly, mice were maintained on water containing
antibiotics (sulfamethoxazole/trimethoprim) for one week before BMT until four
weeks after BMT. Recipient mice were irradiated with a total of 900 Rads from a
cesium source that was delivered in 2 doses within 3 to 4 hours. Bone marrow–
derived cells of male TERT+/+ or TERT-/- mice were obtained from the tibias and
femurs of donor mice and were injected into the tail vein of 8-week-old irradiated
male LDLr-/- recipient mice (1.2×107 cells per mouse, n=10 with TERT+/+ and n=7
with TERT-/-). After four weeks of recovery, a saturated fat-enriched diet was fed
for 12 weeks until the end of the study (Harlan Teklad TD.88137). All studies were
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performed with the approval of the University of Kentucky Institutional Animal Care
and Use Committee.

Atherosclerosis Quantification
En face atherosclerosis was quantified as lesion area on the intimal surface
of aortic arches. The entire aorta from the aortic root to the common iliac arteries
was removed from the sacrificed mice. The intimal surface is exposed by a
longitudinal cut through the inner curvature of the aortic arch and down the anterior
aspect of the remaining aorta. The tissue is then pinned to a dark surface, and the
lesions are observed through a dissecting microscope. The area of atherosclerotic
lesions was quantified and represented as percent of the total intimal surface.

Quantification of Macrophage and Foam Cell Accumulation
Aortic roots were frozen in OCT media (Tissue-Tek, Sakura Finetek,
Torrance, CA) and serial 10 µm sections were cut as previously described 103.
Accumulation of lipids in lesions was visualized by staining with Oil Red O.
Macrophages were detected by immunohistochemistry staining using anti-CD68
antibody (ab955, Abcam). Percentage of macrophage and lipid (Oil Red O
positive) area in aortic root plaques was calculated using computer-assisted image
analysis (Image-Pro, Media Cybernetics, Rockville, MD).
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Telomere Length Quantification
For quantification of telomere length using real-time PCR, DNA was isolated
from bone marrow differentiated macrophages (BMDM) of G1TERT+/+, G1TERT/-, G3TERT-/-, was isolated harvested from TERT-/- samples were run in triplicate
with 35 ng of DNA per reaction using an iCycler and SYBR Green I system (BioRad) as described. Telomere repeat copy number data were normalized to 36B4
as the single-copy gene. Below lists the primer sequences.
tel 1: 5'-GTTTTTGAGGGTGAGGGTGAGGGTGAGGGTGAGGGT-3';
tel 2: 5'-TCCCGACTATCCCTATCCCTATCCCTATCCCTATCCCTA-3';
36B4 forward: 5'-CAACCCAGCTCTGGAGAAAC-3';
36B4 reverse: 5'-AAGCCTGGAAGAAGGAGGTC-3'.
Quantitative fluorescence in situ hybridization on metaphase chromosomes
was performed using Cy-3 labeled (CCCTAA) PNA probe (Telomere PNA Fish
Kit/Cy3, Dako, K5326) to analyze the telomeric sequences in BMDM. Cells were
counterstained with DAPI to visualize the chromosomes.

Quantification of Total Cholesterol Concentration and LipoproteinCholesterol Distribution
Total

plasma

cholesterol

concentration

and

lipoprotein-cholesterol

distribution were analyzed as previously described. Briefly, total plasma
cholesterol was measured by an enzymatic colorimetric method using the Wako
Cholesterol E kit (Wako Chemicals, Richmond, VA). Lipoprotein-cholesterol
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distribution was detected by size exclusion chromatography using a fast
performance liquid chromatographic machine (Pharmacia GE Healthcare Life
Sciences, Pittsburgh, PA).

Cell Culture
Mouse BMDM were isolated from the femurs of mice and differentiated
using Dulbecco's modified Eagle's medium (DMEM, Invitrogen) supplemented with
20% fetal bovine serum and 30% L929 cell-conditioned medium for ten days.
BMDM isolated from G1TERT-/- mice or wild-type littermates (n = 6/group) were
treated with 100 ng/ml lipopolysaccharide (LPS) for the indicated time before RNA
or whole cell lysate collection.

NanoString Gene Expression Analysis
Inflammatory gene expression was profiled using nCounter GX mouse
inflammation kit consisting of 184 inflammation-related genes and six internal
reference genes. Briefly, RNA was collected from cells with Trizol (Invitrogen,
Grand Island, NY). 10ng of purified RNA was hybridized against the nCounter GX
mouse inflammation kit (NanoString Technologies, Seattle, WA) and data were
analyzed using nSolver Analysis Software (NanoString Technologies, Seattle,
WA). The geometric mean of the code counts for the positive control genes was
used for normalization.
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Gene Ontology Enrichment Analysis
LPS-induced inflammatory genes changed more than 1.5 fold by TERT
deletion are included in Gene Ontology (GO) biological process enrichment
analysis. Enrichment analysis was performed using the Gene Ontology
Consortium (Http: //geneontology.org/page/go-enrichment-analysis) based on
biological process terms.

Western Blotting
Western blotting was performed as described using antibodies against pSTAT3 (Tyr705) (9131, cell signaling), total STAT3 (12640, cell signaling), and
GAPDH (FL 335, Santa Cruz).

Flow Cytometry
For phenotypic identification of hematopoietic stem cells (HSC), progenitor
cells, and mature hematopoietic cells, cells were stained with cell surface markers
and analyzed by flow cytometry. Bone marrow cells were stained with the
differentiated lineage cell markers (CD5, CD3, B220, Mac-1, Gr-1, and Ter119
from BD Pharmingen, San Jose, CA) and stem cell markers (Sca-1 from
Invitrogen, Grand Island, NY, c-kit from BD Pharmingen, San Jose, CA). The HSCenriched population is negative for the lineage markers but positive for Sca-1 and
c-kit (Lin-Sca-1+c-kit+). Committed progenitor cells, macrophage and dendritic
progenitors (MDP) were identified by the markers of CD16/CD32 (eBioscience,
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San Diego, CA), and CD115 (BD Pharmingen, San Jose, CA) and were identified
as Lin-Sca-1- c-kit+ CD16/CD32+CD115+. Dead cells were excluded by propidium
iodide selection. Bone marrow cells were analyzed and sorted on a BD FacsAria
II flow cytometer (Becton Dickinson, San Jose, CA). Each experimental group was
sorted independently. Flow cytometry and fluorescence-activated cell sorting
(FACS) data were analyzed using FlowJo software (Tree Star, Ashland, OR)
For identification of mature hematopoietic cells in blood, granulocytes were
identified as CD3e-CD19-NK1.1-CD11b+Ly6Ghi; total monocytes were identified
as CD3e-CD19-NK1.1-Ly6G-CD11b+CD115+, and monocyte subsets were
identified as Ly6C+ monocytes or Ly6C- monocytes by Ly6C fluorescence
intensity gated on total monocytes. Antibodies used for staining are as follows:
APC-Cy7 mouse CD11c, FITC mouse Ly6C, PE-cy7 mouse Ly6G, Percp-cy5.5
mouse CD11b (BD Biosciences, San Jose, CA); PE anti-mouse CD115
(Biolegend, San Diego, CA). Antibodies were used according to the manufacturer's
protocol. Cellular fluorescence was assessed with FACSCalibur (BD Biosciences,
San Jose, CA) and data were analyzed with Cell Quest software (version3.3,
Becton Dickinson, San Jose, CA).

Transfection of HEK 293 Cells
HEK 293 cells were transiently transfected with a TERT or green fluorescent
protein expression vector using Lipofectamine 2000 (Invitrogen, Grand Island, NY)
as described. 24 hours after transfection, cells were treated with LPS (1ug/ml) or
IL-6 (10ng/ml) for 30 minutes before whole cell lysates were collected.
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Statistical Analysis
Results were represented as means or medians depending on the
distribution of data. Unpaired Student's t-test was used to compare the means
between two independent groups on a single variable. The effect of TERT on
atherosclerosis was compared using the Kruskal-Wallis test followed by Dunn Test
post hoc analysis. P values <0.05 were considered to be statistically significant.

4.4

Results

4.4.1 TERT Is Expressed in Macrophages from Atherosclerotic Lesions in
Human Coronary Artery
To confirm that TERT is expressed in complex atherosclerotic lesions in
vivo, we performed immunohistochemical analysis on human coronary arteries.
Consistent with our earlier report, we found significant TERT expression within the
atherosclerotic lesions of human coronary arteries whereas in healthy arteries its
presence is negligible. Unusually high levels of TERT expression were observed
in the macrophage-rich shoulder region of advanced atherosclerotic lesions. As
shown by immunofluorescent staining, TERT colocalized with macrophage CD68
in the atherosclerotic lesions (Figure 4.1. A-B). These observations confirm a
pathological overexpression of TERT by macrophages in human atherosclerotic
lesions.

85

4.4.2 Telomere Length Is Preserved in Early Generation of TERT-Deficient
Mice
TERT-/- mice (The Jackson Laboratory, Stock Number 005423) were used
to test whether TERT deletion affects atherosclerosis formation. First generation
G1TERT-/- mice derived from heterozygote founder mice exhibited normal
telomere lengths and no phenotypes associated with telomere attrition. However,
intercrossing of G1TERT-/- mice results in progressive telomere loss in
subsequent generations. Therefore, this unique system is useful in two aspects: it
allowed the investigation of telomere-independent functions of TERT in G1TERT/- mice, as well as the phenotypes that occur as a result of telomere attrition in the
third generation G3TERT-/- mice. The described alterations of telomere attrition
are documented in Figure 4.2. A-C.

4.4.3 Early and Late Generations of TERT-Deficient Mice Show
Comparable Reduction in Atherosclerosis Formation
While TERT expression is upregulated in the atherosclerotic lesions, it is
not known whether TERT expression contributes to atherosclerosis development.
To address this question, we generated an atherosclerosis mouse model by
crossbreeding G1TERT-/- or G3TERT-/- mice with LDLr-/- and fed a highcholesterol diet. G1TERT-/-LDLr-/- mice developed fewer atherosclerotic lesions
compared to littermate G1TERT+/+LDLr-/- mice, but no difference was found
between G1 and G3TERT-/- LDLr-/- mice (Figure 4.3. A-E), indicating that TERT
deletion in the presence of normal telomere length decreases atherosclerosis
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through a mechanism that is not associated with telomere shortening. TERT
deletion did not affect plasma cholesterol concentration and lipoprotein distribution
(Figure 4.4. A-B), indicating an intrinsic role of TERT to promote atherosclerosis
formation.

4.4.4 TERT Deficiency in Bone Marrow Prevents Atherosclerosis
Formation and Macrophage Recruitment in LDLr-/- Mice
Given that the expression of TERT by infiltrating macrophages in
atherosclerotic plaques was significantly higher compared to that of normal control
arteries, and whole body TERT deletion ameliorated atherosclerotic formation, we
hypothesize that the aberrant TERT expression in macrophages is key to the
development of atherosclerosis through enhanced vascular inflammation. Bone
marrow of TERT-null donors was transplanted to LDLr-/- mice which resulted in
the depletion of TERT in the hematopoietic lineage. As depicted in Figure 4.5.AD, macrophage infiltration and aortic lipid content were decreased in these
chimeric mice after 12 weeks of the atherogenic diet, indicating that the selective
deletion of TERT in bone marrow prevented atherosclerosis formation by
decreasing macrophage recruitment into the arterial wall.
As monocytosis resulted from hypercholesterolemia-induce hematopoiesis
contributes to atherosclerosis, we next quantified bone marrow resident HSC and
MDP populations as well as the leukocyte and monocyte subsets sampled from
systemic circulation. Bone marrow deletion of TERT did not change the counts of
all the cell sets examined (Figure 4.6. A-D). Therefore, the proliferation of HSC and
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MDP, as well as the corresponding monocyte differentiation, are not the potential
mechanisms for TERT-induced atherosclerosis formation.

4.4.5 Inflammatory Genes Are Silenced in G1TERT-/- Macrophages
The observations that TERT deletion reduces atherosclerosis formation in
mice with normal telomeres and monocyte counts, led us to hypothesize that TERT
induces atherosclerosis through mechanisms other than the well-established
functions of TERT in telomere maintenance. Since TERT has recently emerged as
a transcriptional regulator to modulate the expression of genes independently of
its telomerase activity, we employed the NanoString technique to analyze
transcript levels of 184 inflammatory genes in BMDM induced by LPS treatment.
As shown in Figure 4.7. A-C, multiple genes associated with atherosclerosis
formation were found to be expressed at significantly lower levels in G1TERT-/BMDM. These include a host of inflammatory cytokines known to be involved in
atherosclerosis formation, including IL-6, TNFα, IL-1α and IL-1β, and various
members of the CC/CXC chemokine family. These findings indicate that TERT
may be required for the expression of inflammatory genes in macrophages without
affecting telomere homeostasis.

4.4.6 TERT Activates STAT3 Signaling
As shown in Figure 4.8. GO enrichment analysis of TERT-regulated target
genes using the “biological processes” terms revealed that significantly enriched
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processes (P ≤ 0.01) include chemotaxis, cellular response to IL-1 or IFNɣ, and
STAT cascade activation. These hypothesis-generating data indicate that tyrosine
phosphorylation of STAT protein may constitute an underlying mechanism of
TERT-regulated chemokine and cytokine secretion in macrophages. To address
this question, we next investigated whether TERT-deletion in G1TERT-/- BMDM
affected STAT3 phosphorylation as the underlying transcriptional mechanism of
TERT-regulated chemokine and cytokine expression. As depicted in Figure 4.9. AD, LPS-induced STAT3 phosphorylation was reduced in G1TERT-/- BMDM. Using
a transgenic mouse model of TERT overexpression (TERT-Tg, kindly provided by
Dr. Chiang) we confirmed that TERT overexpression in BMDM activated STAT3
phosphorylation. In addition, STAT3 activation by TERT was also observed in
human 293 cells stimulated with either LPS or IL-6. Furthermore, we identified
decreased p-STAT3 levels in atherosclerotic plaque-associated macrophages in
LDLr-/- mice with a bone marrow deletion of TERT (Figure 4.10. A-B).

4.5

Discussion
Macrophages are a critical source of the chronic inflammation and vascular

remodeling processes that are key to the initiation and development of
atherosclerosis formation156. Among the mechanisms that orchestrate tissue
remodeling and repair, telomerase activation is thought to control essential cellular
functions including cell activation, replicative lifespan, differentiation, and
proliferation157. An upregulated expression of TERT, the catalytic subunit of
telomerase, was observed in activated macrophages during atherosclerosis
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formation71. However, the mechanism that underlies this regulation and functional
consequences remains unknown. In the current study, we demonstrate that
genetic TERT depletion prevents atherosclerosis formation in both early and late
generation TERT-deficient mice. Based on these observation, we infer that TERTdeficiency protects from atherosclerosis through mechanisms other than telomere
attrition. Similarly, atherosclerosis development was decreased in chimeric LDLr/- mice with TERT deletion in hematopoietic stem cells following bone marrow
transplantation. In isolated macrophages, TERT deficiency reduced the
expression of multiple chemokines, which are well known to be causally involved
in the formation of atherosclerosis. All regulated target genes are STAT3-induced
genes, consistent with results obtained from our GO enrichment analysis.
Furthermore, we documented a decrease of STAT3 phosphorylation in TERTdeficient BMDM while TERT overexpression enhanced STAT3 phosphorylation in
mouse BMDM and in human 293 cells. Finally, decreased STAT3 activation was
confirmed in vivo by a decrease of STAT3 phosphorylation in macrophages of
atherosclerotic plaques isolated from LDLr-/- mice with TERT-depleted bone
marrow. These findings suggest that genetic TERT deficiency reduces
atherosclerosis formation by silencing inflammatory chemokine transcription
through altered STAT3-dependent signaling.
Telomere length shortening with successive cell divisions has been
proposed to serve as biomarker of biological aging67. Therefore, there has been a
growing interest in utilizing telomere extension as a preventive strategy against
age-related diseases, including atherosclerosis62. However, previous studies have
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identified that telomere length and telomerase activity are increased in human
atherosclerosis, particularly in leukocytes isolated directly from unstable coronary
artery plaques69,

70.

Consistent with this finding, we observed increased TERT

expression in macrophages isolated from human atherosclerotic lesions71.
Importantly, TERT deficiency in this macrophage population was shown to protect
mice against atherosclerosis. Furthermore, atherosclerosis was decreased to a
similar extent in LDLr-/- mice crossbred with either early generation or late
generation of TERT-/- mice. These data indicate that the mechanism of
atherosclerosis prevention associated with genetic TERT deletion is dependent on
TERT deletion but independent of telomere length maintenance because telomere
length in the early generation of TERT-/- mice was indistinguishable from the wildtype littermates. In addition to our findings, numerous studies have identified
telomere-independent functions of TERT involved in essential biological
processes, including cellular proliferation, differentiation, apoptosis, and DNA
repair response48. Therefore, it is possible that TERT functions through an
alternative mechanism to regulate the viability and function of cells within the
arterial wall, ultimately affecting the outcome of atherosclerotic development.
However, the similar degree of atherosclerosis prevention in G1 and G3 TERTdeficient mice cannot be interpreted by telomere length variation during the
process of atherosclerosis formation. Increased telomere uncapping following
telomere erosion could provoke important consequences, including chromosomal
end-to-end fusions, aneuploidy, and impaired stress responses158. Moreover, to
date, there is no evidence from human studies showing that telomere attrition in
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leukocytes causes atherosclerosis. In contrast to the general notion that short
telomere length constitutes a hallmark of cardiovascular events68, there was a
decrease in atherosclerosis in mice with short telomeres due to the proliferative
limitation of immune cells84. Therefore, the role of telomere shortening in
atherosclerosis is inconclusive. Our current result indicate that TERT deletion
attenuates atherosclerosis formation through a mechanism that is likely unrelated
to telomere length regulation.
TERT expression in vascular cells, including VSMC and endothelial cells
(EC), is critical for cellular functions and adaptations during vascular remodeling
and may exert anti-atherosclerotic effects through the protection against cellular
senescence30, 31, 72, 73. Therefore, the absence of TERT in these resident cells in
our whole-body TERT deletion experiments may confound our mechanistic
interpretation on the pro-inflammatory role of TERT specifically in macrophages.
Consequently, chimeric LDLr-/- mice with hematopoietic deletion of TERT using
bone marrow transplantation enabled us to extend these observations and
determine whether TERT-dependent activation of macrophages contributes to
atherosclerosis formation159. Similarly, bone marrow deletion of TERT suppresses
atherosclerosis

development

and

macrophage

accumulation

within

the

atherosclerotic lesion, implying a macrophage-specific effect of TERT to promote
atherosclerosis formation. TERT expression in macrophages is induced during the
activation of immune cells. Multiple studies have revealed that TERT activates
various inflammatory signaling pathways, including MAP-kinase89 and NF-kB
signaling58, and effect that is mediated through telomere maintenance-
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independent mechanisms. In line with these findings, our current study shows that
TERT deletion reduces the expression of multiple inflammatory cytokines and
prevents STAT3 activation. STAT3 signaling pathway is activated by a broad range
of growth factors and cytokines160. Following phosphorylation, activated STAT3
transiently translocates from the cytoplasm to the nucleus, where it functions as a
core transcription factor regulating the expression of a large number of genes
associated with proliferation, survival, and inflammation161. During innate
immunity, STAT3 serves as an essential downstream target of Toll-like receptor 4
(TLR4)162 and IFNɣ pathways163 and is involved in the extensive network of the
inflammatory signaling pathways, including MAP-kinase16, NF-κB164, and PI3K
signaling165. Therefore, STAT3 is increasingly recognized as a central signaling
molecule to control cellular adaption in response to environmental stimuli or stress
responses in EC, VSMC, and inflammatory cells166. In macrophages, STAT3
activation polarizes macrophages from the pro-inflammatory M1 to the antiinflammatory M2 type and exacerbates or reduces inflammation in a contextdependent manner24,

167, 168.

Given the multiple functions of STAT3 in various

biological processes and the complex interactive network between STAT3 and
other inflammatory signaling pathways, our study demonstrates a novel permissive
effect of TERT on pro-inflammatory macrophages through the activation of STAT3.
Telomerase activity is upregulated in response to cytokine-induced
proliferation and cell cycle activation in human hematopoietic cells169. Moreover,
ectopic overexpression of TERT is directly associated with the proliferative
capacity of stem cells and may exert an additional role in lineage differentiation170,
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171.

Therefore, we examined the proliferation and differentiation of HSC, progenitor

cells, peripheral leukocytes and monocytes in LDLr-/- mice reconstituted with
TERT-/- bone marrow. As expected, bone marrow deletion of TERT did not affect
the numbers or composition of these cell lineages. Previously it has been
demonstrated that critical telomere shortening reduces the response to
hematopoietic ablation158 and HSC engraftment172. However, in our studies
telomere shortening was not evident in leukocytes isolated from first generation
TERT-deficient mice173. The dissociation of telomerase activity and telomere
maintenance in human HSC was also noted by Wang et al.174. Furthermore,
multiple studies have identified that the prolonged self-renewal of HSC is not
limited by TERT deletion173, 175. All these findings indicate that stem cells from
early-generation TERT−/− mice with normal telomere lengths can provide efficient
hematopoietic recovery with an adequate amount of functional daughter cells.
Therefore, TERT contribution to atherosclerosis formation is unlikely a result of
alterations in leukocytosis or monocytosis, a well-established mechanism for
atherosclerosis formation7, 176-178.
In summary, the current study demonstrates a TERT-dependent activation
of the STAT3 signaling pathway and pro-inflammatory macrophage phenotype,
which consequently contributes to atherosclerosis formation. Our findings provide
novel insights into the mechanisms controlling inflammatory gene expression and
characterize TERT as a previously unrecognized regulator of atherosclerosis.

94

Figure 4.1 TERT is Expressed in Macrophages of Human Coronary Artery
Atherosclerotic Lesions.
A. Representative IHC and IF images of serial sections of human coronary
arteries from healthy or atherosclerosis patient. Segments of healthy (Left) and
atherosclerotic (Right) human coronary arteries were harvested during an
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autopsy. For immunohistochemistry staining (IHC), paraffin-embedded sections
were stained for TERT, followed by hematoxylin counterstaining. TERT positive
staining is red. Note the lack of TERT staining in normal coronary arteries
compared with the abundant immunoreactivity against TERT in the shoulder
region of atherosclerotic lesions. The serial sections of those used for IHC were
applied for immunofluorescence staining (IF) to detect TERT and macrophage
co-localization in the atherosclerotic lesion. Sections were stained for
macrophage marker CD68 (green), TERT (red), and counterstained with 4′,6diamidino-2-phenylindole (DAPI) to visualize nuclei (blue, lower left panel). The
merged images show the composite staining. The co-localization of CD68 and
TERT immunoreactivity is yellow. Scale bar, 100µm. B. Quantification of TERTpositive macrophages within human coronary artery atherosclerotic lesion.
Paraffin-embedded sections of healthy (n=5) and atherosclerotic (n=3) human
coronary arteries were stained for TERT and macrophage marker CD68 by IF
as described in A. The number of TERT-positive macrophages within the
atherosclerotic lesions was counted from four equally distributed sites on each
coronary artery segment using software ImageJ. Results are presented as mean
± SEM (*P<0.05 vs. normal control).
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Figure 4.2 Telomere Lengths are Preserved in G1TERT-/- mice but
Significantly Decreased in G3TERT-/- Mice.
A-B. Quantification of telomere lengths by real-time PCR in bone marrow
differentiated macrophages from (A) TERT+/+, G1TERT-/- and G3TERT-/- mice
(n=3 per group) and (B) TERT+/+LDLr-/-, G1TERT-/-LDLr-/- and G3TERT-/-LDLr-/mice (n=5 per group). The copy number of telomere repeats was normalized to
that of a single-copy gene (36B4). Values are mean ± SEM (* p<0.05 vs.
TERT+/+). C. Representative telomeric fluorescence in situ hybridization assay
on metaphase chromosomes of TERT+/+, G1TERT-/- and G3TERT-/- bone
marrow differentiated macrophages. DAPI-stained chromosomes and Cy-3–
labeled telomeres are shown in blue and red, respectively.
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Figure 4.3 Early and Late Generation of TERT-Deficient Mice Present
Comparable Reduction in Atherosclerosis Formation.
A. TERT-/-LDLr-/- mice developed fewer atherosclerotic lesions compared with
TERT+/+LDLr-/- mice but no difference was found between G1TERT-/-LDLr-/and G3TERT-/-LDLr-/-. Thoracic atherosclerotic lesion size was measured by
en face analysis. The effect of TERT on atherosclerosis was compared using
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the Kruskal-Wallis test followed by Dunn Test post-hoc analysis. Circles and
triangles represent individual mice; diamonds represent medians (* p<0.05 vs.
G1TERT+/+LDLr-/-). B. Quantification of lipid content from oil red O staining.
Circles represent individual mice; diamonds represent medians (* p<0.05 vs.
G1TERT+/+LDLr-/-). C. Representative Oil Red O staining of aortic root
sections. Neutral lipids are stained red. Scale bar, 200µM. D. Quantification of
macrophage content from macrophage immunostaining. Circles represent
individual mice; diamonds represent medians (* p<0.05 vs. G1TERT+/+LDLr-/-).
E. Representative immunostaining of aortic root sections using rabbit antimouse CD68 antibody to label macrophages. Positive cells are stained red.
Scale bar, 200µM.
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Figure 4.4 TERT Deletion does not Affect Plasma Cholesterol
Concentration and Lipoprotein Distribution.
A. Total plasma cholesterol (TC) concentration measured by an enzymatic
colorimetric method. Values are mean ± SEM. B. Lipoprotein cholesterol
distribution analyzed by size exclusion chromatography. Values represent each
fraction by mean ± SEM.
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Figure 4.5 Early and late generation of TERT-deficient mice present
comparable reduction in atherosclerosis formation.
Bone marrow transplantation (BMT) was applied to conditionally delete TERT
expression in the hematopoietic system. LDLr-/- mice reconstituted with wildtype
or TERT-deficient bone marrow were fed on an atherogenic diet for 12 weeks,
then atherosclerosis was analyzed by quantification of lipid and macrophage
content in the aortic roots. A. Quantification of lipid content from Oil Red O
staining. Circles represent individual mice; diamonds represent medians (*
p<0.05 vs. BMT G1TERT+/+LDLr-/-). B. Representative Oil Red O staining of
aortic root sections. Neutral lipids are stained red. Scale bar, 200µM. C.
Quantification of macrophage content from macrophage immunostaining.
Circles represent individual mice; diamonds represent medians (* p<0.05 vs.
BMT G1TERT+/+LDLr-/-). D. Representative immunostaining of aortic root
sections using rabbit anti-mouse CD68 antibody to label macrophages. Positive
cells are stained red. Scale bar, 200µM.
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Figure 4.6 Bone Marrow Deletion of TERT Does not Alter the Counts of
HSC, MDP, and Blood Cells.
A. Quantification of hematopoietic stem cells (HSC) and macrophage and dendritic
progenitors (MDP) in bone marrow of chimeric LDLr-/- mice received TERT+/+ or
TERT-/- bone marrow (n=10 per group) using flow cytometry. Values are mean ±
SEM B. Quantification of differential white blood cell populations in LDLr-/- mice
reconstituted with TERT+/+ or TERT-/- bone marrow (n=10 per group) analyzed
by flow cytometry. T, T cells; B, B cells; Gran, granulocytes; Mono, monocytes;
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NK, natural killer T cells; DC, dendritic cells. Values are mean ± SEM. C.
Quantification of monocyte subsets in the blood of LDLr-/- mice reconstituted with
TERT+/+ or TERT-/- bone marrow (n=10 per group) by flow cytometry. Values are
mean ± SEM. D. Gating strategy for identification of HSC, MDP, and leukocytes
by flow cytometry.
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Figure 4.7 TERT-Deficient Macrophages Display Silenced Inflammatory
Gene Expression.
A. G1TERT-/- or G1TERT+/+ BMDM were treated with 100ng/ml LPS for 8
hours. Inflammatory gene expression was analyzed by the NanoString nCounter
Analysis System. A. Heat map of LPS-induced genes changed more than twofold with TERT deletion. Each colored square on the heat map represents the
relative transcript abundance (in log2 space) of each gene with the high
expression being red and the low expression being green. Each column
represents one group (n=3 per group) and each row shows the transcript level
of one gene. B-C. NanoString expression graphs of atherosclerosis-related
inflammatory genes that changed more than two-fold with TERT deletion. Data
are presented as fold increase relative to untreated cells. Values are mean±
SEM.
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Figure 4.8 Gene Ontology Enrichment Analysis of TERT-Target Genes.
LPS-induced inflammatory genes changed more than 1.5 fold by TERT
deletion are included in gene ontology (GO) biological process enrichment
analysis. Enrichment analysis was performed using the Gene Ontology
Consortium (http://geneontology.org/page/go-enrichment-analysis) based on
biological process terms. P-value of every enriched biological process is
indicated at the end of each column. IL-1: interleukin-1; interferon-gamma:
IFNɣ;

TNF:

tumor

necrosis

factor;

lipopolysaccharide:

lipopolysaccharides; ERK: extracellular signal–regulated kinases.
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LPS:

Figure 4.9 TERT Activates STAT3 Signaling Pathway.
A. Inhibition of STAT3 phosphorylation in TERT-deficient BMDM. G1TERT-/- and
G1TERT+/+ BMDM were stimulated with 100ng/ml LPS for 1 hour; P-STAT3 and
total STAT3 protein expression were detected by Western blot analysis. B.
Enhanced STAT3 phosphorylation in the BMDM overexpressing TERT (TERTTg). TERT-Tg and TERT+/+ BMDM were treated with 100ng/ml LPS for 1 hour;
P-STAT3 and total STAT3 protein expression were detected by Western blot
analysis. C-D. Increased STAT3 phosphorylation in HEK 293 cells with TERT
overexpression. HEK 293 cells were transfected with plasmids that overexpress
TERT. 24 hours after transfection, cells were treated with 1µg/ml LPS (C) or
10ng/ml IL-6 (D) for 30 minutes before whole cell lysates were collected. PSTAT3 and total STAT3 protein expression were detected by Western blot
analysis.
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Figure 4.10 Reduced STAT3 Activation within the Macrophages in the
Atherosclerotic Lesions of LDLr-/- Mice with Bone Marrow Deletion of
TERT
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A. Representative images of the p-STAT3 and CD68 co-staining in the sections
of aortic roots from LDLr-/- mice transplanted with TERT+/+ or TERT-/- bone
marrow. Sections were stained for macrophage marker CD68 (green), p-STAT3
(red), and counterstained with 4′, 6-diamidino-2-phenylindole (DAPI) to visualize
nuclei (blue). The merged images show the composite staining. The colocalization of CD68 and p-STAT3 immunoreactivity is yellow. Scale bar, 100µm.
B.

Quantification of

p-STAT3-positive macrophages within the aortic

atherosclerotic lesion. The area of p-STAT3 positive macrophages within the
atherosclerotic lesions was counted from three equally distributed sites on each
segment using software ImageJ. Results are presented as mean ± SEM
(*P<0.05 vs. BMT TERT+/+LDLr-/-).
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5

CHAPTER FIVE

General Discussion

5.1

Summary
Telomerase reverse transcriptase (TERT) is the catalytic subunit of

telomerase and the limiting factor for enzymatic activity. Expression of TERT and
telomerase activity is increased in atherosclerotic plaques. However, the role of
TERT dysregulation during atherosclerosis formation remains unknown.
The work herein first identified a multi-tiered regulation of TERT expression
in VSMC through HDAC inhibition. In VSMC treated with a small molecular HDAC
inhibitor, the abundance of TERT transcript increased through transactivation of
the TERT promoter. At the protein level, in contrast, HDAC inhibition accelerated
the turnover of TERT towards degradation, which reduced overall telomerase
activity and induced senescence. Furthermore, during vascular remodeling, TERT
protein expression in the neointima was suppressed by HDAC inhibition. These
data illustrate a differential regulation of TERT transcription and protein stability by
HDAC inhibition. Moreover, the current study found that TERT deficiency reduces
neointima formation following guidewire-induced arterial injury. Studies in SMC
isolated from TERT-deficient and TERT overexpressing mice established that
TERT is necessary and sufficient for cell proliferation without affecting telomere
length. TERT deficiency induced cell cycle arrest at G1 phase without causing
senescence albeit hyperphosphorylation of the retinoblastoma protein. This
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proliferative arrest was associated with stable silencing of the E2F1-dependent Sphase gene expression program which could not be reversed by ectopic
overexpression of E2F1. Chromatin immunoprecipitation and accessibility assays
revealed that TERT was recruited to chromatin regions containing E2F1 binding
sites and facilitated the permissive histone modifications to allow the access of
these locations to the transcription factor. These data indicate a promotional effect
of TERT on SMC growth and neointima formation through epigenetic regulation of
proliferative gene expression. Also, we investigated the function of TERT in
macrophages during atherosclerosis formation. TERT expression was upregulated
in activated macrophages during atherosclerosis formation. To study the role of
TERT in this process, we crossbred TERT-deficient mice with LDL-receptordeficient (LDLr-/-) mice to generate first generation G1TERT-/-LDLr-/- offsprings,
which were then intercrossed to obtain the third generation G3TERT-/-LDLr-/mice. G1TERT-/-LDLr-/- mice exhibited no telomere shortening while severe
telomere attrition was evident in G3TERT-/-LDLr-/- mice. When fed an atherogenic
diet, G1TERT-/-LDLr-/- and G3TERT-/-LDLr-/- mice were both protected from
atherosclerosis formation compared to their wild-type controls, indicating that
genetic TERT-deletion prevents atherosclerosis, and formation of the disease is
not affected by telomere attrition. Similarly, atherosclerotic development was
decreased in chimeric LDLr-/- mice with stem cell deletion of TERT generated by
bone marrow transplantation. TERT deficiency reduced the accumulation of
macrophages in atherosclerotic lesions and inhibited the expression of
proinflammatory cytokines, including CXC1/2/3, CCL3, CCL5, CCL21, CCR7, IL-
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6, and IL-1α. Gene ontology (GO) enrichment analysis of inflammatory genes
altered by TERT deletion identified an overrepresentation of STAT3-dependent,
which was confirmed by western blotting showing a decreased tyrosine
phosphorylation of the STAT3 protein in TERT-deficient BMDM. These findings
suggest that the protective effect of TERT deletion on atherosclerosis formation is
likely a result of suppressed STAT3 signaling in macrophages, which silences the
expression of a variety of proinflammatory cytokines.
In conclusion, the current study identifies that TERT dysregulation within
atherosclerotic plaques plays a causative role in atherosclerosis and injuryinduced neointima formation by promoting VSMC proliferation and macrophage
inflammatory response. These findings identify a novel mechanism by which TERT
might exacerbate pathological vascular remodeling under diseased conditions,
which may provide a new therapeutic target.

5.2

TERT Dysregulation During Vascular Remodeling

5.2.1 TERT Expression Is Up-Regulated in the VSMC and Macrophages
During Vascular Remodeling
Telomeres get shortened with each cell division due to the “end replication
problem”42. Therefore, the inverse relationship between telomere attrition and age
makes telomere length to be proposed as a candidate biomarker of aging68, which
is a major risk factor for atherosclerosis179. Consequently, leukocyte telomere
attrition is suggested to correlate with vascular aging and cardiovascular events,
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although the clinical association has not been consistent68. Furthermore, telomere
length measured in peripheral leukocytes is not a surrogate marker for other
tissues180. In line with this concept is Huzen’s finding that atherosclerosis patients
had shorter leukocyte telomeres, but longer plaque telomeres that are related to
plaque characteristics and development of restenosis following endarterectomy69.
Therefore, the relationship between short leukocyte telomere length and
atherosclerosis severity is inconclusive, and telomere integrity in local tissue may
change differently from that of peripheral blood cells.
Telomerase, an enzyme with its RNA template and reverse transcriptase,
is the primary mechanism to prevent telomere erosion by synthesizing telomeric
DNA25. Telomerase activity and the expression of its catalytic subunit TERT are
suppressed in differentiated cells29,

181.

In line with this concept, expression of

TERT and telomerase activity was found to be negligible in the normal vasculature.
In the pathogenic vascular remodeling process preceding atherosclerosis and
injury-induced neointima formation, however, TERT expression and telomerase
was reactivated30, 31, 71. Our findings are consistent with an earlier study in which
an increased TERT expression and telomerase activity were identified in the aorta
of hypertension132. Data published by Matthews et al. also noted that TERT
expression was readily detectable in lesional macrophages78. Similarly,
neutrophils isolated from coronary artery plaques of patients with unstable angina
was found to have abnormal telomerase activity70. In contrast, EC in the aortic
wall during aneurysm formation182 and VSMC in the atherosclerotic fibrous cap78
were thought to express low levels of TERT rendering the telomerase inert.
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However, a technical drawback was acknowledged in these two studies, that both
measured TERT and telomerase expression using immunohistochemistry
staining, which only provides the semi-quantitative assessment thus presents a
risk of experimental bias. With repeated analysis in three different mouse models,
our group provides compelling evidence for the reactivation of telomerase and
TERT expression in the artery during vascular remodeling.

5.2.2 Multi-Layer Control of TERT Expression During Vascular Remodeling
Transcriptional control constitutes the primary mechanism of regulation of
TERT expression183. Our previous studies observed a profound induction of TERT
expression and telomerase activity in the neointima following vascular injury
mediated by Ets-1 or E2F1 dependent transactivation of the TERT promoter30, 31;
besides, a similar change in TERT expression and telomerase activity was
detected in atherosclerotic lesional macrophages as a result of NF-kB signaling71.
This early research from our group indicates that pro-atherogenic mediators
upregulate TERT transcription through promoter activation.
In addition to transcriptional regulation, TERT expression is also subject to
modulation via post-transcriptional, post-translational modifications, as well as
epigenetic mechanisms27. In the current study, we illustrate a differential control at
the transcript versus protein levels of TERT expression by HDAC inhibition.
Quiescent somatic cells epigenetically silence the TERT promoter activity by
histone deacetylation38, an effect that is reversed during malignant cell growth due
to HDAC sequestration41. Our observation of enhanced TERT promoter activity
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upon HDAC inhibition is consistent with several prior studies38, 39, 111. However, we
also noticed a decrease in the abundance of TERT protein and telomerase activity
due to enhanced degradation of the TERT protein. The two-stage control of TERT
expression by HDAC inhibition might be a result of enhanced global acetylation of
nonhistone proteins following HDAC inhibitor treatment. HDAC inhibitors have
been shown to promote protein degradation through post-translational modification
in addition to the classical epigenetic mechanism115, 116. Moreover, although TERT
expression is primarily regulated at the transcriptional level, posttranslational
modification and proteasome-mediated degradation of TERT have been reported
to play a significant role in telomerase inactivation117, 118. Therefore, our findings
support the notion that TERT expression is subject to a coordinated multi-layer
control of expression, in which HDAC inhibitor-induced protein acetylation may
modulate levels of epigenetic and post-translational regulation of TERT protein
expression.

5.3

TERT in Atherosclerosis Formation

5.3.1 Telomere-Independent Function of TERT in Vascular Remodeling
The mitogenic phenotype of VSMC triggers the intimal hyperplasia at the
early stage of atherosclerosis3. In the present study, we illustrate a previously
unrecognized epigenetic regulation of TERT over E2F1 target genes in
proliferating VSMC. TERT associates with histone acetyltransferase P300 to open
chromatin regions at E2F1 consensus sites and facilitates E2F1 target gene
transcription to induce cell cycle progression. As macrophage-mediated
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inflammation plays a fundamental role in all stages of disease from initiation
through

progression

and,

ultimately,

the

thrombotic

complications

of

atherosclerosis, we continued to investigate the macrophage-specific function of
TERT. Our data show that TERT deficiency suppresses atherosclerosis formation
through

silencing

STAT3-regulatedinflammatory

genes

in

macrophages.

Moreover, preliminary results on the function of TERT in VSMC and macrophages
were corroborated by similar findings from in vivo experiments in the early
generation of TERT-deficient mice with normal telomere length, suggesting a
telomere-independent function of TERT during vascular remodeling. In concert
with these observations was our previous study that also documented that TERTdeficient macrophages per se could prevent MMP-2 transcription and aortic
aneurysm formation with no significant telomere erosion 57. In support of our
findings of this novel function of TERT, results from other groups show that TERT
modulates the chromatin state184, interacts with DNA-modifying enzymes60, and
activates a variety of genes regulating proliferation55, 152, 185, apoptosis46, 148, 186, 187,
inflammation58,

86, 188,

angiogenesis189,

190,

and stem cell mobilization191,

192.

Therefore, TERT may regulate cell function not only through canonic telomere
elongation but also through non-canonical mechanisms that require further
investigation.

5.3.2 TERT Facilitates Chromatin Remodeling
Using chromatin immunoprecipitation assays, we demonstrate that TERT
promotes E2F1 target gene transcription by increasing chromatin accessibility
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through p300-medaited histone acetylation. Other groups also identified that TERT
modulates chromatin architecture through interaction with BRG1 (Brahma-related
gene 1)60, 184, a subunit of chromatin remodeling complex SWI/SNF with ATPase
activity. The model explains the synergistic effects of histone acetylation and ATPdependent chromatin remodeling complexes on transcriptional activation, during
which additional chromatin remodeling complexes, including the SWI/SNF
complex, are recruited to restructure the nucleosomes and expose the binding
sites of transcriptional factors35. In line with this concept, accumulating evidence
supports that the p300 coactivator interacts with the chromatin-modifying BRG1
complex during transcriptional activation to stimulate histone acetylation193,

194.

Specifically, Zhang et al. characterized a BAF (BRG1-associated factors)mediated interaction of p300 and BRG1 during transcriptional regulation195.
Consistent with these findings, our observation of TERT binding to p300 may
provide a mechanism by which TERT permits transcription of proliferative genes.
Therefore, our current findings identify a novel role of TERT in the epigenetic
regulation of VSMC proliferation.

5.4

Future Study

5.4.1 Define

the

Core

Transcriptional

Network

of

TERT

During

Atherosclerosis Formation
Our study characterizes TERT as a transcriptional coactivator to generate
permissive chromatin through association with p300 to promote histone H3
acetylation.

Histone acetylation marks genes that are actively transcribed196.
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Therefore, the binding of TERT to the enhancer-associated protein p300 supports
that TERT serves as a bridge between the core transcriptional machinery and the
functional regulatory elements during transcriptional activation. A similar
mechanism of chromatin regulation has been described by the interaction between
BRG1 and TERT to facilitate the transcription of Wnt target genes60. Furthermore,
TERT has been shown to regulate transcription via an association with the
transcriptional machinery. For example, TERT increases RNA pol III binding to
target genomic regions197; TERT physically binds to p65 and affects genome-wide
p65 occupancy of target chromatin58. Furthermore, many studies have implied that
TERT binds to various promoter regions and activates target gene transcription.
For example, TERT stimulates RNA polymerase I transcription and enhances
ribosomal biogenesis198. Based on these findings, we hypothesize that TERT is
involved in a transcriptional network that ultimately controls essential cellular
functions, including proliferation, inflammation, apoptosis, and DNA damage
response pathways. Given that TERT is highly expressed and exhibits potent
telomerase activity within the atherosclerotic lesions, it will be important to
understand related mechanisms by which TERT regulates cellular functions and
accelerates disease progression.

5.4.2 Define the Pharmacological Application of TERT for Atherosclerosis
Treatment
A hallmark of atherosclerosis development and neointimal remodeling is
aberrant VSMC proliferation2, which can be effectively suppressed by HDAC
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inhibitors101. HDAC inhibitors have been characterized as a unique category of
anti-cancer drugs with four HDAC inhibitors approved by the United States Food
and Drug Administration. HDAC inhibitors target TERT expression in cancer cells40
121.

Our current study further demonstrates a novel mechanism underlying the anti-

mitotic efficacy of HDAC inhibitors during neointima formation involving the
suppression of TERT expression. Moreover, TERT dysregulation within the arterial
wall contributes to atherosclerosis and neointima formation by promoting VSMC
proliferation and macrophage inflammatory responses. These findings prompt an
intriguing question: Is TERT a reliable pharmacological target for atherosclerosis
therapy? There are a variety of telomerase-inhibiting compounds under
investigation for cancer therapy since most cancer cells exhibit high telomerase
activity compared to normal somatic cells. However, there is currently no TERT
targeting compound suitable for selectively targeting tumor cells without affecting
the normal stem cell population, highlighting the importance of cell-specific
targeting for future pharmacological development.
In summary, the current study highlights an aberrant over-expression of
TERT within atherosclerotic lesions and a novel role of TERT in VSMC mitosis and
macrophage inflammation. However, in order to design potent TERT-targeting
therapeutics for vascular diseases and avoid potential side effects, a gap for future
development remains. In particular, understanding mechanisms of gene regulation
by TERT and pathways of cell-specific targeting of TERT will constitute important
avenues for future research.
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Figure 5.1 Proposed TERT Function Over Transcription Regulation.
TERT plays a role in bridging the core transcriptional machinery to the functional
regulatory elements during transcriptional activation. A, TERT acts as a
transcriptional factor binding to the DNA motif to activate target promoters. The
nucleotides in color are the presumed sequence motif of TERT in hESC-1 cells
based on genome-wide ChIP-seq results197. B, TERT recruits transcriptional
coactivators to the core machinery thus enhancing transcriptional efficiency.
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APPENDICES

Figure A.1 A, TERT depletion using siRNA-mediated knock-down. Human
coronary artery SMC were transfected with TERT siRNA or scrambled control,
serum deprived for 24 hours, and stimulated with FBS for 48 hours. TERT
expression was analyzed by Western Blotting. Co-hybridization for GAPDH was
used

to

control

for

equal

protein

loading.

B-C,

Adenovirus-mediated

overexpression of TERT in human coronary artery SMC. Cells were transduced
for the indicated time points with 30 PFU of adenoviral constructs and analyzed for
TERT expression by Western Blotting (B). Transduction efficiency of co-expressed
GFP was confirmed by fluorescent microscopy at 50 PFU (C). The autoradiograms
and images shown are representative of at least three independently performed
experiments using different cell preparations. (D) TERT depletion using a lentiviral
vector expressing TERT shRNA. Human coronary artery SMC were transduced
with lentiviral vector expressing TERT shRNA (shTERT) or nontargeting control
(shCTL) for 24 hours. mRNA expression of TERT was analyzed 48 hours after
transduction by quantitative real-time PCR and normalized to transcript levels of
the housekeeping gene TBP. Values are mean ± SEM (*P<0.05 versus shCTL).
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Figure A.2 Telomere lengths of SMC isolated from G1TERT+/+, G1TERT- /- and
G3TERT-/- mice. Quantification of telomere lengths in G1TERT+/+, G1TERT-/and G3TERT-/- SMC using real-time PCR (n=3 mice per group). Data are
presented as fold change relative to 36B4 (mean ± SEM, *P P<0.05 versus
G1TERT+/+).
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Figure A.3. A, G1TERT+/+ and G1TERT-/- SMC were stained for senescenceassociated b-galactosidase activity (objective magnification, x20). The images
shown are representative of three independently performed experiments using
different cell preparations. B, Transcript levels of p16, p21, p53, p27, CDK4, CDK6,
E2F2, E2F3, and E2F4 in G1TERT+/+ and G1TERT-/- SMC. mRNA expression
levels of the indicated genes were analyzed by real-time RT-PCR and normalized
to transcript levels of the housekeeping gene transcription factor TFIIB. Data are
presented as mean ± SEM, (n=4/group).
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Figure A.4 TERT deletion does not affect E2F1 expression in SMC. Western
blotting for E2F1 expression in whole cell lysates isolated from quiescent SMC (FBS) stimulated with FBS (+ FBS). Co-hybridization for GAPDH was used to
control for equal protein loading. The autoradiogram shown is representative of
three independently performed experiments using different cell preparations.
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Figure A.5 TERT deletion does not affect E2F1 expression in SMC. Western
blotting for E2F1 expression in whole cell lysates isolated from quiescent SMC (FBS) stimulated with FBS (+ FBS). Co-hybridization for GAPDH was used to
control for equal protein loading. The autoradiogram shown is representative of
three independently performed experiments using different cell preparations.
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Figure A.6 TERT binding is dependent on the presence of the E2F1 binding site
in the MCM7 promoter. Chromatin upstream of the E2F1 promoter sequence was
not immunoprecipitated by the TERT antibody. Data are presented as mean ±
SEM (#P<0.05 versus quiescent shCTL, *P<0.05 versus FBS treated shCTL).
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Table I: Primers used in this study
Name

Use

Sequence
F: 5’-GGCACAGGGCTTACTCTCAG-3’

Murine MCM7

RT-PCR
R: 5’-AGGAGACTGGTCCACACCAC-3’
F: 5’-CTTGCTGCGGGTAAAGAGAC-3’

Murine Cyclin A

RT-PCR
R: 5’-CGCAGCAGAAGCTCAAGGC-3’
F: 5’-TTGGAATCCCAGAACAGGAG-3’

Murine PCNA

RT-PCR
R: 5’-ATTGCCAAGCTCTCCACTTG-3’
F: 5’-TGTGGGGCAGAGACCTAC-3’

Human MCM7

RT-PCR
R: 5’-CTGGGCAATCCTTGTGTT-3’
F: 5’-CCTCTGAGCCAGGAGACATTTTC-3’

Murine P53

RT-PCR
R: 5’-AAGCCCAGGTGGAAGCCATAGTTG-3’
F: 5’-CCTTGAACCTGCTTGTCCTC-3’

Murine Rb

RT-PCR
R: 5’-GGGCAAGGGAGGTAGATTTC-3’
F: 5’-CTTTGTGTACCGCTGGGAAC-3’

Murine P16

RT-PCR
R: 5’-CGCTAGCATCGCTAGAAGTG-3’
F: 5’-GTACTTCCTCTGCCCTGCTGC-3’

Murine P21

RT-PCR
R:5’-GCTTGGAGTGATAGAAATGGTCAGG-3’
F: 5’-GCCGGGATATGGAAGAAG-3’

Murine P27

RT-PCR
R:5’-ATGCCGGTCCTCAGAGTT-3’
F: 5’-GCTGCCACTCGATATGAACC-3’

Murine CDK4

RT-PCR
R: 5’-CCTTAACAAGGCCACCTCAC-3’
F: 5’-GAGAAGGACAGCCTGAGTCG-3’

Murine CDK6

RT-PCR
R: 5’-CCTCACTGGTCTGCACTCG-3’
F: 5’-ACGGCGCAACCTACAAAGAG-3’

Murine E2F2

RT-PCR
R: 5’-GTCTGCGTGTAAAGCGAAGT-3’

Murine E2F3

RT-PCR

F: 5’-AAACGCGGTATGATACGTCCC-3’
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R: 5’-CCATCAGGAGACTGGCTCAG-3’
F: 5’-CTCACCACCAAGTTCGTGTC-3’
Murine E2F4

RT-PCR
R: 5’-TCTCGATCAGACCGATGCCTT-3’
F: 5’-CTCTCCCAAGAGTCACATGTCC-3’

Murine TFIIB

RT-PCR
R: 5’-CAATAACTCGGTCCCCTACAAC-3’
F: 5’-GGAGAGTTCTGGGATTGTACCGC-3’

Human TBP

RT-PCR
R: 5’-ATATTCGGCGTTTCGGGCAC-3’

E2F1 target sites
F: 5’-GCTTTAAGAAACACTCCTCCCACAC-3’
within the murine

ChIP
R: 5’-GCCAGCCCCTAACTTTAACCAATCAA-3’

MCM7 promoter
E2F1 target sites
F:5’-CCTCCCAGGCTCCTACCC-3’
within the murine

ChIP
R: 5’-GGCCTACAGCGACAACTACC-3’

PCNA promoter
E2F1 target sites
F:5’-CCACTGAGCAGCAGAGATCGGC-3’
within the murine

ChIP
R: 5’-GGCGGGAGGAGCGTAGAGC-3’

Cyclin A promoter
Upstream sequence
F: 5’-CACATTGCGTGAGATGGTTC-3’

of E2F1 binding
ChIP

R: 5’-GGTGGCCACAACCTTAGAAA-3’

sites in the murine
MCM7 promoter
Upstream sequence

F: 5’-CGGGTTCATCTTCAGCCTAA-3’

of E2F1 binding
ChIP

R: 5’- GCGTCGCTCTGAACTTTTCT-3’

sites in the murine
PCNA promoter

F: 5’-AGGACAATTGGGACAGCATT-3’

Upstream sequence
ChIP
of E2F1 binding

R: 5’-CTAGGCAGGAGCGTATGGAT-3’
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sites in the murine
Cyclin A promoter
E2F1 target sites
F: 5’- ATGTTGGCCAGGCTGATTTC -3’
within the human

ChIP
R: 5’- CTCCCAGGACTGGTTCATTG-3’

MCM7 promoter
E2F1 target sites in
F: 5’- CTGGCTGCTGCGCGA-3’
the human PCNA

ChIP
R: 5’- CACCACCCGCTTTGTGACT-3’

promoter
E2F1 target sites in
F:5’-TCACCTGGCTTGTCAGTCAC-3’
the human Cyclin A

ChIP
R:5’-GACAGAGCTGGGGCTTGG-3’

promoter
Upstream sequence
F: 5’-GTAGAGGCGGAGTTTCACCA-3’

of E2F1 binding
ChIP

R: 5’-CTCCCAGGACTGGTTCATTG-3’

sites in the human
MCM7 promoter
Upstream sequence

F: 5’-TGTGATGCTATGTTTTAAAGAGGTACTGA-3’

of E2F1 binding
ChIP

R: 5’- AATTTTATGCCACGTACATCTTTTTATC-3’

sites in the human
PCNA promoter
Upstream sequence

F: 5’-CGCTTTCATTGGTCCATTTC-3’

of E2F1 binding
ChIP

R: 5’-CCGGCCAAAGAATAGTCGTA-3’

sites in the human
Cyclin A promoter
E2F1 binding sites
in the murine
MCM7 promoter

ChART
PCR

F: 5’-GCTTTAAGAAACACTCCTCCCACAC-3’
R: 5’-GCCAGCCCCTAACTTTAACCAATCAA-3’

(-346 to -176)
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upstream sequence
of the murine
MCM7 promoter

ChART
PCR

F:5’-ACATCACGACCACCACTGTC-3’
R: 5’-GGGGTAGGGTAGCTGGGTAG-3’

( -620 to -513)
tel 1:
Telomere
5’-GTTTTTGAGGGTGAGGGTGAGGGTGAGGGTGAGGGT-3’
Telomere

Length
tel 2:
Analysis
5’-TCCCGACTATCCCTATCCCTATCCCTATCCCTATCCCTA-3’
Telomere
F: 5’-CAACCCAGCTCTGGAGAAAC-3’

36B4

Length
R: 5’-AAGCCTGGAAGAAGGAGGTC-3’
Analysis
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